Stem definition | Drug id | CAS RN |
---|---|---|
1767 | 113-45-1 |
Dose | Unit | Route |
---|---|---|
30 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 4.29 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 22 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.42 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.85 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 4.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 5, 1955 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Suicidal ideation | 342.73 | 11.18 | 300 | 36623 | 55085 | 50513116 |
Product quality issue | 255.40 | 11.18 | 198 | 36725 | 30660 | 50537541 |
Anxiety | 246.22 | 11.18 | 454 | 36469 | 177152 | 50391049 |
Product substitution issue | 223.41 | 11.18 | 135 | 36788 | 13922 | 50554279 |
Agitation | 212.55 | 11.18 | 227 | 36696 | 53157 | 50515044 |
Depression | 204.66 | 11.18 | 403 | 36520 | 165020 | 50403181 |
Aggression | 173.61 | 11.18 | 135 | 36788 | 20981 | 50547220 |
Tachycardia | 165.21 | 11.18 | 276 | 36647 | 99487 | 50468714 |
Disturbance in attention | 161.55 | 11.18 | 153 | 36770 | 31033 | 50537168 |
Drug abuse | 160.72 | 11.18 | 208 | 36715 | 59638 | 50508563 |
No adverse event | 155.67 | 11.18 | 155 | 36768 | 33423 | 50534778 |
Attention deficit hyperactivity disorder | 149.63 | 11.18 | 59 | 36864 | 2370 | 50565831 |
Irritability | 135.06 | 11.18 | 133 | 36790 | 28293 | 50539908 |
Abnormal behaviour | 134.72 | 11.18 | 113 | 36810 | 19545 | 50548656 |
Pre-existing condition improved | 130.72 | 11.18 | 75 | 36848 | 7022 | 50561179 |
Tic | 128.65 | 11.18 | 44 | 36879 | 1173 | 50567028 |
Intentional overdose | 119.93 | 11.18 | 185 | 36738 | 62319 | 50505882 |
Precocious puberty | 112.04 | 11.18 | 27 | 36896 | 189 | 50568012 |
Cataplexy | 102.85 | 11.18 | 36 | 36887 | 1030 | 50567171 |
Suicide attempt | 99.06 | 11.18 | 153 | 36770 | 51579 | 50516622 |
Mydriasis | 96.26 | 11.18 | 72 | 36851 | 10555 | 50557646 |
Tremor | 90.33 | 11.18 | 234 | 36689 | 114669 | 50453532 |
Intentional self-injury | 89.66 | 11.18 | 97 | 36826 | 23015 | 50545186 |
Application site erythema | 89.08 | 11.18 | 50 | 36873 | 4488 | 50563713 |
Hallucination, auditory | 89.05 | 11.18 | 69 | 36854 | 10659 | 50557542 |
Psychotic disorder | 88.95 | 11.18 | 94 | 36829 | 21718 | 50546483 |
Joint swelling | 83.92 | 11.18 | 37 | 36886 | 245249 | 50322952 |
Therapeutic response unexpected | 82.24 | 11.18 | 78 | 36845 | 15837 | 50552364 |
Contraindicated product administered | 79.95 | 11.18 | 8 | 36915 | 148950 | 50419251 |
Pulmonary malformation | 77.88 | 11.18 | 20 | 36903 | 187 | 50568014 |
Wrong technique in product usage process | 75.52 | 11.18 | 141 | 36782 | 55369 | 50512832 |
Toxicity to various agents | 72.47 | 11.18 | 327 | 36596 | 212172 | 50356029 |
Glossodynia | 71.40 | 11.18 | 3 | 36920 | 115566 | 50452635 |
Product administered at inappropriate site | 71.00 | 11.18 | 35 | 36888 | 2408 | 50565793 |
Overdose | 70.19 | 11.18 | 195 | 36728 | 99532 | 50468669 |
Psychomotor hyperactivity | 69.00 | 11.18 | 56 | 36867 | 9245 | 50558956 |
Sleep apnoea syndrome | 68.82 | 11.18 | 86 | 36837 | 23782 | 50544419 |
Apathy | 68.05 | 11.18 | 51 | 36872 | 7497 | 50560704 |
Somnambulism | 67.35 | 11.18 | 43 | 36880 | 4881 | 50563320 |
Application site irritation | 65.08 | 11.18 | 29 | 36894 | 1586 | 50566615 |
Insomnia | 64.85 | 11.18 | 276 | 36647 | 174589 | 50393612 |
Chorea | 63.58 | 11.18 | 27 | 36896 | 1313 | 50566888 |
Feeling abnormal | 62.89 | 11.18 | 218 | 36705 | 125274 | 50442927 |
Rheumatoid arthritis | 62.55 | 11.18 | 35 | 36888 | 202515 | 50365686 |
Diarrhoea | 60.85 | 11.18 | 223 | 36700 | 588253 | 49979948 |
Rapid eye movement sleep behaviour disorder | 60.12 | 11.18 | 16 | 36907 | 174 | 50568027 |
Somnolence | 58.52 | 11.18 | 246 | 36677 | 154739 | 50413462 |
Bruxism | 58.33 | 11.18 | 33 | 36890 | 3007 | 50565194 |
Product colour issue | 57.92 | 11.18 | 20 | 36903 | 549 | 50567652 |
Hallucination | 57.91 | 11.18 | 114 | 36809 | 46543 | 50521658 |
Intentional product misuse | 57.78 | 11.18 | 114 | 36809 | 46620 | 50521581 |
Acute kidney injury | 57.68 | 11.18 | 49 | 36874 | 228009 | 50340192 |
Product administration error | 56.83 | 11.18 | 71 | 36852 | 19628 | 50548573 |
Panic attack | 56.26 | 11.18 | 70 | 36853 | 19272 | 50548929 |
Swelling | 56.09 | 11.18 | 39 | 36884 | 200833 | 50367368 |
Arthralgia | 55.28 | 11.18 | 152 | 36771 | 438550 | 50129651 |
Dystonia | 55.14 | 11.18 | 55 | 36868 | 11871 | 50556330 |
Systemic lupus erythematosus | 55.14 | 11.18 | 17 | 36906 | 140605 | 50427596 |
Drug dependence | 55.07 | 11.18 | 70 | 36853 | 19689 | 50548512 |
Enuresis | 54.53 | 11.18 | 28 | 36895 | 2101 | 50566100 |
Obsessive-compulsive disorder | 52.85 | 11.18 | 32 | 36891 | 3308 | 50564893 |
Dyskinesia | 52.75 | 11.18 | 82 | 36841 | 27779 | 50540422 |
Social anxiety disorder | 52.35 | 11.18 | 17 | 36906 | 384 | 50567817 |
Lung cyst | 51.97 | 11.18 | 14 | 36909 | 160 | 50568041 |
Infusion related reaction | 51.33 | 11.18 | 30 | 36893 | 169527 | 50398674 |
Arthropathy | 50.62 | 11.18 | 26 | 36897 | 157880 | 50410321 |
Educational problem | 49.21 | 11.18 | 16 | 36907 | 363 | 50567838 |
Lower respiratory tract infection | 48.82 | 11.18 | 6 | 36917 | 95195 | 50473006 |
Impulsive behaviour | 48.76 | 11.18 | 23 | 36900 | 1435 | 50566766 |
Parasomnia | 48.28 | 11.18 | 16 | 36907 | 386 | 50567815 |
Anaemia | 47.63 | 11.18 | 69 | 36854 | 252387 | 50315814 |
Headache | 45.78 | 11.18 | 567 | 36356 | 505968 | 50062233 |
Peripheral swelling | 45.38 | 11.18 | 50 | 36873 | 205886 | 50362315 |
Euphoric mood | 44.80 | 11.18 | 31 | 36892 | 4024 | 50564177 |
Crying | 44.23 | 11.18 | 64 | 36859 | 20352 | 50547849 |
Completed suicide | 44.17 | 11.18 | 202 | 36721 | 131687 | 50436514 |
Neutropenia | 43.63 | 11.18 | 27 | 36896 | 147938 | 50420263 |
Muscle twitching | 43.52 | 11.18 | 55 | 36868 | 15376 | 50552825 |
Muscle contracture | 43.34 | 11.18 | 20 | 36903 | 1187 | 50567014 |
Withdrawal syndrome | 42.35 | 11.18 | 58 | 36865 | 17532 | 50550669 |
Growth retardation | 42.30 | 11.18 | 19 | 36904 | 1059 | 50567142 |
Drug diversion | 41.64 | 11.18 | 17 | 36906 | 748 | 50567453 |
Wound | 41.09 | 11.18 | 13 | 36910 | 105781 | 50462420 |
Restlessness | 40.73 | 11.18 | 69 | 36854 | 25104 | 50543097 |
Infection | 40.34 | 11.18 | 40 | 36883 | 172914 | 50395287 |
Pericarditis | 40.25 | 11.18 | 5 | 36918 | 78684 | 50489517 |
Memory impairment | 39.84 | 11.18 | 138 | 36785 | 79222 | 50488979 |
Application site pruritus | 39.80 | 11.18 | 28 | 36895 | 3731 | 50564470 |
Febrile neutropenia | 39.76 | 11.18 | 11 | 36912 | 97656 | 50470545 |
Respiratory tract malformation | 39.58 | 11.18 | 10 | 36913 | 87 | 50568114 |
Hallucination, visual | 38.90 | 11.18 | 54 | 36869 | 16528 | 50551673 |
Pre-eclampsia | 38.86 | 11.18 | 38 | 36885 | 8006 | 50560195 |
Maternal exposure during breast feeding | 38.61 | 11.18 | 26 | 36897 | 3228 | 50564973 |
Splenic infarction | 38.47 | 11.18 | 20 | 36903 | 1540 | 50566661 |
Treatment failure | 38.03 | 11.18 | 27 | 36896 | 137610 | 50430591 |
Migraine | 37.87 | 11.18 | 131 | 36792 | 75149 | 50493052 |
Paranoia | 37.64 | 11.18 | 42 | 36881 | 10306 | 50557895 |
Heart rate increased | 37.63 | 11.18 | 133 | 36790 | 77117 | 50491084 |
Seizure | 37.59 | 11.18 | 178 | 36745 | 117696 | 50450505 |
Abdominal discomfort | 37.44 | 11.18 | 70 | 36853 | 231571 | 50336630 |
Depressed mood | 37.32 | 11.18 | 79 | 36844 | 33944 | 50534257 |
Rash | 36.93 | 11.18 | 179 | 36744 | 437292 | 50130909 |
Hyperventilation | 36.85 | 11.18 | 31 | 36892 | 5378 | 50562823 |
Bipolar disorder | 36.60 | 11.18 | 34 | 36889 | 6723 | 50561478 |
Drug intolerance | 36.49 | 11.18 | 65 | 36858 | 219039 | 50349162 |
Anger | 36.18 | 11.18 | 43 | 36880 | 11290 | 50556911 |
Blister | 35.95 | 11.18 | 9 | 36914 | 85409 | 50482792 |
Haemoglobin decreased | 35.09 | 11.18 | 25 | 36898 | 127191 | 50441010 |
Emotional disorder | 34.68 | 11.18 | 43 | 36880 | 11793 | 50556408 |
Dyspnoea | 34.56 | 11.18 | 246 | 36677 | 547362 | 50020839 |
Affective disorder | 33.88 | 11.18 | 29 | 36894 | 5152 | 50563049 |
Application site urticaria | 33.77 | 11.18 | 11 | 36912 | 251 | 50567950 |
Multiple sclerosis relapse | 33.20 | 11.18 | 87 | 36836 | 42877 | 50525324 |
Delusion of parasitosis | 33.19 | 11.18 | 6 | 36917 | 6 | 50568195 |
Negative thoughts | 33.14 | 11.18 | 15 | 36908 | 851 | 50567350 |
Death | 33.04 | 11.18 | 124 | 36799 | 325255 | 50242946 |
Exposure during pregnancy | 32.43 | 11.18 | 174 | 36749 | 120841 | 50447360 |
Livedo reticularis | 32.30 | 11.18 | 20 | 36903 | 2152 | 50566049 |
Feeling jittery | 31.83 | 11.18 | 40 | 36883 | 11120 | 50557081 |
Mania | 30.93 | 11.18 | 39 | 36884 | 10877 | 50557324 |
General physical health deterioration | 30.90 | 11.18 | 35 | 36888 | 142399 | 50425802 |
Snoring | 30.80 | 11.18 | 23 | 36900 | 3361 | 50564840 |
Hepatic enzyme increased | 30.63 | 11.18 | 33 | 36890 | 137347 | 50430854 |
Weight decreased | 29.95 | 11.18 | 269 | 36654 | 220976 | 50347225 |
Exposure via breast milk | 29.63 | 11.18 | 17 | 36906 | 1591 | 50566610 |
Sepsis | 29.56 | 11.18 | 32 | 36891 | 132893 | 50435308 |
Solar urticaria | 29.05 | 11.18 | 7 | 36916 | 49 | 50568152 |
Serotonin syndrome | 28.99 | 11.18 | 59 | 36864 | 24654 | 50543547 |
Perinatal depression | 28.95 | 11.18 | 12 | 36911 | 549 | 50567652 |
Drug hypersensitivity | 28.61 | 11.18 | 91 | 36832 | 250919 | 50317282 |
Sleep-related eating disorder | 28.44 | 11.18 | 13 | 36910 | 755 | 50567446 |
Post-traumatic stress disorder | 27.96 | 11.18 | 24 | 36899 | 4279 | 50563922 |
Mood altered | 27.60 | 11.18 | 40 | 36883 | 12733 | 50555468 |
Hypersomnia | 27.50 | 11.18 | 44 | 36879 | 15270 | 50552931 |
Lactation disorder | 27.39 | 11.18 | 10 | 36913 | 324 | 50567877 |
Pneumonia | 27.37 | 11.18 | 163 | 36760 | 378238 | 50189963 |
Thrombocytopenia | 27.01 | 11.18 | 32 | 36891 | 127641 | 50440560 |
Pancytopenia | 26.67 | 11.18 | 14 | 36909 | 84016 | 50484185 |
Meningitis streptococcal | 26.24 | 11.18 | 8 | 36915 | 146 | 50568055 |
Application site rash | 25.99 | 11.18 | 18 | 36905 | 2339 | 50565862 |
Mobility decreased | 25.85 | 11.18 | 13 | 36910 | 79935 | 50488266 |
Product taste abnormal | 25.77 | 11.18 | 16 | 36907 | 1729 | 50566472 |
Interstitial lung disease | 25.73 | 11.18 | 4 | 36919 | 53172 | 50515029 |
Drug screen negative | 25.59 | 11.18 | 9 | 36914 | 261 | 50567940 |
Optic disc haemorrhage | 25.55 | 11.18 | 6 | 36917 | 37 | 50568164 |
Tachyphrenia | 25.20 | 11.18 | 14 | 36909 | 1231 | 50566970 |
Adhesive tape use | 24.90 | 11.18 | 4 | 36919 | 0 | 50568201 |
Psychiatric symptom | 24.76 | 11.18 | 23 | 36900 | 4547 | 50563654 |
Chronic fatigue syndrome | 24.75 | 11.18 | 13 | 36910 | 1022 | 50567179 |
Maternal exposure during pregnancy | 24.31 | 11.18 | 50 | 36873 | 159728 | 50408473 |
Burnout syndrome | 24.30 | 11.18 | 8 | 36915 | 189 | 50568012 |
Multiple organ dysfunction syndrome | 23.87 | 11.18 | 4 | 36919 | 50333 | 50517868 |
Alopecia | 23.82 | 11.18 | 95 | 36828 | 244952 | 50323249 |
Hangover | 23.78 | 11.18 | 14 | 36909 | 1375 | 50566826 |
Cyanosis | 23.74 | 11.18 | 41 | 36882 | 15143 | 50553058 |
Cardiac failure | 23.64 | 11.18 | 13 | 36910 | 76027 | 50492174 |
Tachypnoea | 23.63 | 11.18 | 40 | 36883 | 14537 | 50553664 |
Mood swings | 23.55 | 11.18 | 42 | 36881 | 15912 | 50552289 |
Wound infection fungal | 23.37 | 11.18 | 7 | 36916 | 120 | 50568081 |
Nightmare | 23.30 | 11.18 | 42 | 36881 | 16044 | 50552157 |
Axonal neuropathy | 23.23 | 11.18 | 12 | 36911 | 912 | 50567289 |
Abnormal sleep-related event | 23.16 | 11.18 | 11 | 36912 | 697 | 50567504 |
Eosinophilic myocarditis | 22.95 | 11.18 | 9 | 36914 | 356 | 50567845 |
Sleep paralysis | 22.88 | 11.18 | 10 | 36913 | 522 | 50567679 |
Cardiac failure congestive | 22.72 | 11.18 | 17 | 36906 | 84365 | 50483836 |
Open angle glaucoma | 22.46 | 11.18 | 8 | 36915 | 241 | 50567960 |
Product prescribing error | 22.21 | 11.18 | 48 | 36875 | 20913 | 50547288 |
Palpitations | 22.08 | 11.18 | 131 | 36792 | 94375 | 50473826 |
Amphetamines positive | 21.69 | 11.18 | 7 | 36916 | 155 | 50568046 |
Logorrhoea | 21.61 | 11.18 | 16 | 36907 | 2308 | 50565893 |
Gastrointestinal haemorrhage | 20.75 | 11.18 | 14 | 36909 | 73307 | 50494894 |
Narcolepsy | 20.67 | 11.18 | 12 | 36911 | 1148 | 50567053 |
Septic shock | 20.52 | 11.18 | 8 | 36915 | 57167 | 50511034 |
Protrusion tongue | 20.51 | 11.18 | 8 | 36915 | 312 | 50567889 |
Hyperkalaemia | 20.36 | 11.18 | 5 | 36918 | 48084 | 50520117 |
Blood pressure increased | 20.16 | 11.18 | 166 | 36757 | 132966 | 50435235 |
Antiphospholipid syndrome | 20.13 | 11.18 | 13 | 36910 | 1504 | 50566697 |
Long QT syndrome congenital | 19.84 | 11.18 | 5 | 36918 | 43 | 50568158 |
Application site discolouration | 19.60 | 11.18 | 10 | 36913 | 740 | 50567461 |
Sensory level abnormal | 19.50 | 11.18 | 6 | 36917 | 113 | 50568088 |
Hallucination, tactile | 19.47 | 11.18 | 7 | 36916 | 217 | 50567984 |
Renal failure | 19.24 | 11.18 | 30 | 36893 | 106603 | 50461598 |
Trichotillomania | 19.16 | 11.18 | 6 | 36917 | 120 | 50568081 |
Libido decreased | 19.10 | 11.18 | 15 | 36908 | 2361 | 50565840 |
Discomfort | 19.08 | 11.18 | 31 | 36892 | 108349 | 50459852 |
Substance abuse | 19.03 | 11.18 | 19 | 36904 | 4105 | 50564096 |
Initial insomnia | 19.02 | 11.18 | 21 | 36902 | 5094 | 50563107 |
Bezoar | 19.00 | 11.18 | 12 | 36911 | 1336 | 50566865 |
Social avoidant behaviour | 18.99 | 11.18 | 16 | 36907 | 2781 | 50565420 |
Atrial fibrillation | 18.96 | 11.18 | 28 | 36895 | 101717 | 50466484 |
Pain | 18.93 | 11.18 | 303 | 36620 | 578600 | 49989601 |
Compulsive lip biting | 18.67 | 11.18 | 3 | 36920 | 0 | 50568201 |
Drug withdrawal syndrome | 18.57 | 11.18 | 50 | 36873 | 25031 | 50543170 |
Incorrect product administration duration | 18.54 | 11.18 | 28 | 36895 | 9247 | 50558954 |
Application site pain | 18.45 | 11.18 | 18 | 36905 | 3780 | 50564421 |
Pyrexia | 18.40 | 11.18 | 183 | 36740 | 380020 | 50188181 |
Learning disorder | 18.40 | 11.18 | 9 | 36914 | 609 | 50567592 |
Renal impairment | 18.20 | 11.18 | 17 | 36906 | 75644 | 50492557 |
Respiratory failure | 18.08 | 11.18 | 24 | 36899 | 91157 | 50477044 |
Pleural effusion | 17.67 | 11.18 | 20 | 36903 | 81434 | 50486767 |
Impaired healing | 17.60 | 11.18 | 15 | 36908 | 69771 | 50498430 |
Nystagmus | 17.59 | 11.18 | 21 | 36902 | 5540 | 50562661 |
Nervousness | 17.42 | 11.18 | 52 | 36871 | 27599 | 50540602 |
Hypotension | 17.22 | 11.18 | 101 | 36822 | 235368 | 50332833 |
Delusion | 17.13 | 11.18 | 29 | 36894 | 10540 | 50557661 |
Major depression | 17.02 | 11.18 | 23 | 36900 | 6861 | 50561340 |
Folliculitis | 16.76 | 11.18 | 4 | 36919 | 39221 | 50528980 |
Hunger | 16.72 | 11.18 | 18 | 36905 | 4245 | 50563956 |
Product complaint | 16.68 | 11.18 | 30 | 36893 | 11436 | 50556765 |
Platelet count decreased | 16.64 | 11.18 | 30 | 36893 | 100696 | 50467505 |
Bisexuality | 16.59 | 11.18 | 3 | 36920 | 3 | 50568198 |
Thinking abnormal | 16.51 | 11.18 | 27 | 36896 | 9540 | 50558661 |
Acne | 16.50 | 11.18 | 41 | 36882 | 19554 | 50548647 |
Dizziness | 16.50 | 11.18 | 349 | 36574 | 346020 | 50222181 |
Leukopenia | 16.45 | 11.18 | 15 | 36908 | 67513 | 50500688 |
Stress | 16.24 | 11.18 | 80 | 36843 | 53713 | 50514488 |
Tardive dyskinesia | 16.03 | 11.18 | 23 | 36900 | 7256 | 50560945 |
C-reactive protein increased | 15.91 | 11.18 | 15 | 36908 | 66459 | 50501742 |
Therapeutic response changed | 15.87 | 11.18 | 9 | 36914 | 824 | 50567377 |
Foot fracture | 15.84 | 11.18 | 41 | 36882 | 20050 | 50548151 |
Decreased appetite | 15.57 | 11.18 | 219 | 36704 | 200704 | 50367497 |
Schizoaffective disorder bipolar type | 15.48 | 11.18 | 5 | 36918 | 111 | 50568090 |
Mucosal inflammation | 15.46 | 11.18 | 5 | 36918 | 40137 | 50528064 |
Hyperhidrosis | 15.46 | 11.18 | 115 | 36808 | 89311 | 50478890 |
Raynaud's phenomenon | 15.42 | 11.18 | 10 | 36913 | 1166 | 50567035 |
Vasospasm | 15.25 | 11.18 | 8 | 36915 | 627 | 50567574 |
Grimacing | 15.19 | 11.18 | 7 | 36916 | 414 | 50567787 |
Stomatitis | 15.17 | 11.18 | 32 | 36891 | 101312 | 50466889 |
Congenital cystic lung | 15.16 | 11.18 | 4 | 36919 | 42 | 50568159 |
Lactic acidosis | 15.06 | 11.18 | 3 | 36920 | 33352 | 50534849 |
Brain death | 15.06 | 11.18 | 14 | 36909 | 2769 | 50565432 |
Affect lability | 15.00 | 11.18 | 25 | 36898 | 8973 | 50559228 |
Consciousness fluctuating | 14.75 | 11.18 | 8 | 36915 | 671 | 50567530 |
Loss of consciousness | 14.67 | 11.18 | 128 | 36795 | 104225 | 50463976 |
Knee arthroplasty | 14.65 | 11.18 | 4 | 36919 | 35842 | 50532359 |
Body temperature increased | 14.43 | 11.18 | 53 | 36870 | 31288 | 50536913 |
International normalised ratio increased | 13.97 | 11.18 | 7 | 36916 | 43145 | 50525056 |
Hyperacusis | 13.67 | 11.18 | 11 | 36912 | 1793 | 50566408 |
Formication | 13.61 | 11.18 | 15 | 36908 | 3631 | 50564570 |
Heavy menstrual bleeding | 13.60 | 11.18 | 33 | 36890 | 15504 | 50552697 |
Gastric bypass | 13.53 | 11.18 | 10 | 36913 | 1438 | 50566763 |
Phobia | 13.50 | 11.18 | 6 | 36917 | 326 | 50567875 |
Malignant neoplasm progression | 13.44 | 11.18 | 18 | 36905 | 68106 | 50500095 |
Small fibre neuropathy | 13.36 | 11.18 | 5 | 36918 | 174 | 50568027 |
Pelvic inflammatory disease | 13.09 | 11.18 | 10 | 36913 | 1512 | 50566689 |
Treatment noncompliance | 13.06 | 11.18 | 50 | 36873 | 30100 | 50538101 |
Serum serotonin decreased | 12.99 | 11.18 | 3 | 36920 | 17 | 50568184 |
Cerebral artery occlusion | 12.99 | 11.18 | 8 | 36915 | 852 | 50567349 |
Cleft lip and palate | 12.99 | 11.18 | 6 | 36917 | 357 | 50567844 |
Regressive behaviour | 12.97 | 11.18 | 4 | 36919 | 76 | 50568125 |
Diplopia | 12.88 | 11.18 | 37 | 36886 | 19223 | 50548978 |
Rectal haemorrhage | 12.87 | 11.18 | 6 | 36917 | 38552 | 50529649 |
Nephrogenic diabetes insipidus | 12.81 | 11.18 | 8 | 36915 | 873 | 50567328 |
Herpes zoster | 12.69 | 11.18 | 20 | 36903 | 70766 | 50497435 |
Muscle tightness | 12.60 | 11.18 | 25 | 36898 | 10255 | 50557946 |
Mental disorder | 12.59 | 11.18 | 40 | 36883 | 21951 | 50546250 |
Hepatic failure | 12.47 | 11.18 | 4 | 36919 | 32279 | 50535922 |
Gastrointestinal disorder | 12.39 | 11.18 | 32 | 36891 | 94424 | 50473777 |
Distractibility | 12.33 | 11.18 | 6 | 36917 | 401 | 50567800 |
Poor sucking reflex | 12.31 | 11.18 | 5 | 36918 | 217 | 50567984 |
Tongue biting | 12.02 | 11.18 | 9 | 36914 | 1321 | 50566880 |
Horner's syndrome | 11.99 | 11.18 | 3 | 36920 | 25 | 50568176 |
Seizure like phenomena | 11.90 | 11.18 | 8 | 36915 | 990 | 50567211 |
Pruritus | 11.89 | 11.18 | 141 | 36782 | 283427 | 50284774 |
Prehypertension | 11.88 | 11.18 | 3 | 36920 | 26 | 50568175 |
Choreoathetosis | 11.88 | 11.18 | 6 | 36917 | 435 | 50567766 |
Illness | 11.72 | 11.18 | 42 | 36881 | 24498 | 50543703 |
Cough | 11.70 | 11.18 | 116 | 36807 | 241148 | 50327053 |
Radius fracture | 11.63 | 11.18 | 13 | 36910 | 3196 | 50565005 |
Neutrophil percentage increased | 11.55 | 11.18 | 12 | 36911 | 2715 | 50565486 |
Hyponatraemia | 11.54 | 11.18 | 34 | 36889 | 96105 | 50472096 |
Amnesia | 11.46 | 11.18 | 61 | 36862 | 42199 | 50526002 |
Muscle spasms | 11.45 | 11.18 | 141 | 36782 | 125412 | 50442789 |
Disease progression | 11.44 | 11.18 | 34 | 36889 | 95832 | 50472369 |
Oculogyric crisis | 11.40 | 11.18 | 9 | 36914 | 1428 | 50566773 |
Extrapyramidal disorder | 11.39 | 11.18 | 26 | 36897 | 11744 | 50556457 |
Food craving | 11.39 | 11.18 | 9 | 36914 | 1430 | 50566771 |
Petit mal epilepsy | 11.37 | 11.18 | 13 | 36910 | 3276 | 50564925 |
Diaphragmalgia | 11.31 | 11.18 | 4 | 36919 | 118 | 50568083 |
Status epilepticus | 11.23 | 11.18 | 28 | 36895 | 13378 | 50554823 |
Ill-defined disorder | 11.23 | 11.18 | 14 | 36909 | 54640 | 50513561 |
Hepatotoxicity | 11.20 | 11.18 | 3 | 36920 | 27223 | 50540978 |
Drug abuser | 11.19 | 11.18 | 12 | 36911 | 2816 | 50565385 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product quality issue | 895.43 | 13.26 | 430 | 38265 | 15465 | 29520367 |
No adverse event | 651.11 | 13.26 | 358 | 38337 | 17120 | 29518712 |
Aggression | 649.84 | 13.26 | 463 | 38232 | 35078 | 29500754 |
Tic | 523.04 | 13.26 | 162 | 38533 | 1673 | 29534159 |
Agitation | 424.43 | 13.26 | 423 | 38272 | 50881 | 29484951 |
Abnormal behaviour | 410.22 | 13.26 | 296 | 38399 | 22831 | 29513001 |
Suicidal ideation | 366.92 | 13.26 | 328 | 38367 | 34388 | 29501444 |
Product substitution issue | 363.90 | 13.26 | 196 | 38499 | 8976 | 29526856 |
Irritability | 348.93 | 13.26 | 264 | 38431 | 21888 | 29513944 |
Psychomotor hyperactivity | 321.60 | 13.26 | 174 | 38521 | 8039 | 29527793 |
Wrong technique in product usage process | 314.49 | 13.26 | 288 | 38407 | 31140 | 29504692 |
Application site erythema | 306.22 | 13.26 | 112 | 38583 | 1987 | 29533845 |
Attention deficit hyperactivity disorder | 253.51 | 13.26 | 99 | 38596 | 2118 | 29533714 |
Dyskinesia | 253.39 | 13.26 | 210 | 38485 | 19851 | 29515981 |
Dystonia | 225.33 | 13.26 | 147 | 38548 | 9602 | 29526230 |
Growth retardation | 215.53 | 13.26 | 81 | 38614 | 1555 | 29534277 |
Psychotic disorder | 214.27 | 13.26 | 192 | 38503 | 20162 | 29515670 |
Anxiety | 211.62 | 13.26 | 391 | 38304 | 84974 | 29450858 |
Disturbance in attention | 205.82 | 13.26 | 192 | 38503 | 21232 | 29514600 |
Product administration error | 204.40 | 13.26 | 161 | 38534 | 14149 | 29521683 |
Acute kidney injury | 201.35 | 13.26 | 50 | 38645 | 265217 | 29270615 |
Crying | 197.37 | 13.26 | 109 | 38586 | 5242 | 29530590 |
Product administered at inappropriate site | 186.80 | 13.26 | 74 | 38621 | 1646 | 29534186 |
Application site irritation | 168.20 | 13.26 | 53 | 38642 | 581 | 29535251 |
Suicide attempt | 166.47 | 13.26 | 214 | 38481 | 33896 | 29501936 |
Choreoathetosis | 165.93 | 13.26 | 59 | 38636 | 961 | 29534871 |
Application site pruritus | 162.84 | 13.26 | 62 | 38633 | 1235 | 29534597 |
Insomnia | 158.54 | 13.26 | 355 | 38340 | 88406 | 29447426 |
Pneumonia | 153.87 | 13.26 | 117 | 38578 | 320055 | 29215777 |
Incorrect product administration duration | 153.67 | 13.26 | 84 | 38611 | 3957 | 29531875 |
Tachycardia | 150.45 | 13.26 | 308 | 38387 | 72102 | 29463730 |
Intentional product misuse | 149.94 | 13.26 | 205 | 38490 | 34456 | 29501376 |
Depression | 141.47 | 13.26 | 331 | 38364 | 84816 | 29451016 |
Anger | 133.30 | 13.26 | 112 | 38583 | 10778 | 29525054 |
Death | 132.56 | 13.26 | 152 | 38543 | 341932 | 29193900 |
Impulsive behaviour | 129.11 | 13.26 | 59 | 38636 | 1884 | 29533948 |
Hallucination, visual | 127.96 | 13.26 | 126 | 38569 | 14889 | 29520943 |
Disturbance in social behaviour | 117.25 | 13.26 | 53 | 38642 | 1649 | 29534183 |
Intentional overdose | 116.78 | 13.26 | 193 | 38502 | 38335 | 29497497 |
Anaemia | 111.87 | 13.26 | 62 | 38633 | 200889 | 29334943 |
Educational problem | 111.07 | 13.26 | 37 | 38658 | 490 | 29535342 |
Drug dependence | 109.24 | 13.26 | 136 | 38559 | 20845 | 29514987 |
Withdrawal syndrome | 106.46 | 13.26 | 99 | 38596 | 10893 | 29524939 |
Paranoia | 103.55 | 13.26 | 93 | 38602 | 9784 | 29526048 |
Trismus | 103.36 | 13.26 | 54 | 38641 | 2319 | 29533513 |
Palpitations | 101.05 | 13.26 | 165 | 38530 | 32439 | 29503393 |
Drug ineffective | 99.75 | 13.26 | 812 | 37883 | 362358 | 29173474 |
Hallucination | 99.73 | 13.26 | 196 | 38499 | 44516 | 29491316 |
Overdose | 96.07 | 13.26 | 275 | 38420 | 79544 | 29456288 |
Mydriasis | 94.56 | 13.26 | 72 | 38623 | 6013 | 29529819 |
Priapism | 92.41 | 13.26 | 63 | 38632 | 4425 | 29531407 |
Hallucination, auditory | 92.13 | 13.26 | 86 | 38609 | 9507 | 29526325 |
Serotonin syndrome | 91.94 | 13.26 | 114 | 38581 | 17398 | 29518434 |
Oppositional defiant disorder | 91.27 | 13.26 | 32 | 38663 | 499 | 29535333 |
Drug diversion | 88.27 | 13.26 | 35 | 38660 | 780 | 29535052 |
Coronary artery dissection | 87.93 | 13.26 | 25 | 38670 | 186 | 29535646 |
Depressed mood | 87.84 | 13.26 | 108 | 38587 | 16340 | 29519492 |
Diarrhoea | 87.74 | 13.26 | 191 | 38504 | 332507 | 29203325 |
Hypotension | 85.71 | 13.26 | 77 | 38618 | 194277 | 29341555 |
Sleep disorder | 84.65 | 13.26 | 130 | 38565 | 24256 | 29511576 |
Product complaint | 84.09 | 13.26 | 64 | 38631 | 5341 | 29530491 |
Homicidal ideation | 83.80 | 13.26 | 48 | 38647 | 2476 | 29533356 |
Somnolence | 83.05 | 13.26 | 291 | 38404 | 93664 | 29442168 |
Dyspnoea | 82.53 | 13.26 | 192 | 38503 | 326540 | 29209292 |
Febrile neutropenia | 81.41 | 13.26 | 23 | 38672 | 112217 | 29423615 |
Hallucination, tactile | 80.95 | 13.26 | 25 | 38670 | 255 | 29535577 |
Sepsis | 80.82 | 13.26 | 43 | 38652 | 142639 | 29393193 |
Bruxism | 80.42 | 13.26 | 40 | 38655 | 1547 | 29534285 |
Emotional disorder | 80.29 | 13.26 | 60 | 38635 | 4871 | 29530961 |
Product prescribing error | 78.71 | 13.26 | 107 | 38588 | 17869 | 29517963 |
Therapeutic product effect decreased | 77.99 | 13.26 | 139 | 38556 | 29312 | 29506520 |
Trichotillomania | 76.40 | 13.26 | 18 | 38677 | 55 | 29535777 |
Precocious puberty | 75.37 | 13.26 | 20 | 38675 | 111 | 29535721 |
Feeling abnormal | 74.83 | 13.26 | 197 | 38498 | 54248 | 29481584 |
Toxicity to various agents | 73.33 | 13.26 | 432 | 38263 | 173229 | 29362603 |
Application site rash | 73.06 | 13.26 | 30 | 38665 | 734 | 29535098 |
Mood altered | 72.71 | 13.26 | 70 | 38625 | 8041 | 29527791 |
Logorrhoea | 71.94 | 13.26 | 42 | 38653 | 2246 | 29533586 |
Gastrointestinal haemorrhage | 70.75 | 13.26 | 10 | 38685 | 79523 | 29456309 |
Affect lability | 68.25 | 13.26 | 47 | 38648 | 3355 | 29532477 |
Drug abuse | 67.64 | 13.26 | 244 | 38451 | 79639 | 29456193 |
Decreased eye contact | 67.48 | 13.26 | 25 | 38670 | 460 | 29535372 |
Restlessness | 67.15 | 13.26 | 111 | 38584 | 22034 | 29513798 |
Renal failure | 65.31 | 13.26 | 37 | 38658 | 118562 | 29417270 |
Mania | 65.21 | 13.26 | 68 | 38627 | 8595 | 29527237 |
Intentional self-injury | 65.21 | 13.26 | 81 | 38614 | 12380 | 29523452 |
Headache | 63.50 | 13.26 | 417 | 38278 | 173590 | 29362242 |
General physical health deterioration | 62.77 | 13.26 | 28 | 38667 | 102829 | 29433003 |
Product adhesion issue | 62.72 | 13.26 | 33 | 38662 | 1438 | 29534394 |
Euphoric mood | 61.89 | 13.26 | 51 | 38644 | 4774 | 29531058 |
Cardiac failure congestive | 60.75 | 13.26 | 13 | 38682 | 76568 | 29459264 |
Pyrexia | 59.01 | 13.26 | 187 | 38508 | 287435 | 29248397 |
Renal impairment | 58.34 | 13.26 | 17 | 38678 | 81316 | 29454516 |
Obsessive-compulsive disorder | 57.93 | 13.26 | 48 | 38647 | 4528 | 29531304 |
Oromandibular dystonia | 57.23 | 13.26 | 22 | 38673 | 450 | 29535382 |
Speech disorder | 57.20 | 13.26 | 107 | 38588 | 23409 | 29512423 |
Decreased appetite | 57.12 | 13.26 | 355 | 38340 | 144987 | 29390845 |
Interstitial lung disease | 57.01 | 13.26 | 5 | 38690 | 57713 | 29478119 |
Multiple organ dysfunction syndrome | 55.98 | 13.26 | 8 | 38687 | 63108 | 29472724 |
Haemoglobin decreased | 55.23 | 13.26 | 37 | 38658 | 108338 | 29427494 |
Thrombocytopenia | 55.19 | 13.26 | 57 | 38638 | 134766 | 29401066 |
Apathy | 54.83 | 13.26 | 53 | 38642 | 6118 | 29529714 |
Application site pain | 53.26 | 13.26 | 31 | 38664 | 1648 | 29534184 |
Product administered to patient of inappropriate age | 51.67 | 13.26 | 36 | 38659 | 2619 | 29533213 |
Platelet count decreased | 50.36 | 13.26 | 38 | 38657 | 104634 | 29431198 |
Formication | 50.36 | 13.26 | 29 | 38666 | 1511 | 29534321 |
Neutropenia | 50.26 | 13.26 | 59 | 38636 | 131652 | 29404180 |
Therapeutic response unexpected | 49.83 | 13.26 | 59 | 38636 | 8579 | 29527253 |
Drug screen negative | 49.38 | 13.26 | 15 | 38680 | 144 | 29535688 |
Blood creatinine increased | 47.62 | 13.26 | 26 | 38669 | 85076 | 29450756 |
Pancytopenia | 47.14 | 13.26 | 25 | 38670 | 83143 | 29452689 |
Alice in wonderland syndrome | 46.79 | 13.26 | 9 | 38686 | 5 | 29535827 |
Delusion | 46.44 | 13.26 | 65 | 38630 | 11151 | 29524681 |
Product taste abnormal | 46.10 | 13.26 | 24 | 38671 | 1023 | 29534809 |
Application site urticaria | 45.62 | 13.26 | 12 | 38683 | 64 | 29535768 |
Gynaecomastia | 45.56 | 13.26 | 55 | 38640 | 8162 | 29527670 |
Suicidal behaviour | 45.43 | 13.26 | 26 | 38669 | 1339 | 29534493 |
Torticollis | 45.08 | 13.26 | 24 | 38671 | 1071 | 29534761 |
Enuresis | 44.68 | 13.26 | 30 | 38665 | 2054 | 29533778 |
Respiratory failure | 44.54 | 13.26 | 37 | 38658 | 97094 | 29438738 |
Mood swings | 44.29 | 13.26 | 51 | 38644 | 7200 | 29528632 |
Social avoidant behaviour | 43.93 | 13.26 | 34 | 38661 | 2908 | 29532924 |
Oedema peripheral | 41.00 | 13.26 | 45 | 38650 | 103512 | 29432320 |
Raynaud's phenomenon | 40.64 | 13.26 | 15 | 38680 | 273 | 29535559 |
Autism spectrum disorder | 40.59 | 13.26 | 28 | 38667 | 2004 | 29533828 |
Product colour issue | 40.33 | 13.26 | 16 | 38679 | 357 | 29535475 |
Keratoconus | 40.31 | 13.26 | 11 | 38684 | 69 | 29535763 |
Hyperkalaemia | 40.21 | 13.26 | 15 | 38680 | 61377 | 29474455 |
Hypertension | 39.78 | 13.26 | 275 | 38420 | 116339 | 29419493 |
Atrial fibrillation | 38.51 | 13.26 | 49 | 38646 | 105597 | 29430235 |
Hallucinations, mixed | 38.26 | 13.26 | 29 | 38666 | 2404 | 29533428 |
Heart rate increased | 38.21 | 13.26 | 125 | 38570 | 38813 | 29497019 |
Drug use disorder | 37.41 | 13.26 | 33 | 38662 | 3389 | 29532443 |
Hyperkinesia | 36.66 | 13.26 | 24 | 38671 | 1575 | 29534257 |
Extrapyramidal disorder | 36.53 | 13.26 | 57 | 38638 | 10774 | 29525058 |
Product use issue | 36.01 | 13.26 | 148 | 38547 | 51296 | 29484536 |
Increased appetite | 35.94 | 13.26 | 42 | 38653 | 6022 | 29529810 |
Tardive dyskinesia | 35.56 | 13.26 | 39 | 38656 | 5219 | 29530613 |
Asthenia | 35.49 | 13.26 | 153 | 38542 | 215097 | 29320735 |
Septic shock | 35.16 | 13.26 | 19 | 38676 | 62541 | 29473291 |
Dermatillomania | 34.86 | 13.26 | 9 | 38686 | 44 | 29535788 |
Treatment noncompliance | 34.62 | 13.26 | 89 | 38606 | 24138 | 29511694 |
Drug tolerance | 34.61 | 13.26 | 26 | 38669 | 2127 | 29533705 |
Bipolar disorder | 34.48 | 13.26 | 31 | 38664 | 3264 | 29532568 |
White blood cell count decreased | 34.36 | 13.26 | 35 | 38660 | 83327 | 29452505 |
Cardiac failure | 34.17 | 13.26 | 32 | 38663 | 79255 | 29456577 |
Screaming | 33.94 | 13.26 | 21 | 38674 | 1249 | 29534583 |
Ventricular parasystole | 33.84 | 13.26 | 6 | 38689 | 0 | 29535832 |
Rebound effect | 33.70 | 13.26 | 25 | 38670 | 2006 | 29533826 |
Coordination abnormal | 33.67 | 13.26 | 44 | 38651 | 7070 | 29528762 |
Completed suicide | 33.26 | 13.26 | 217 | 38478 | 90029 | 29445803 |
Muscle contracture | 33.20 | 13.26 | 20 | 38675 | 1133 | 29534699 |
Peripheral swelling | 32.13 | 13.26 | 22 | 38673 | 63717 | 29472115 |
Sleep apnoea syndrome | 32.01 | 13.26 | 71 | 38624 | 17528 | 29518304 |
Affective disorder | 31.90 | 13.26 | 29 | 38666 | 3097 | 29532735 |
Tremor | 31.61 | 13.26 | 184 | 38511 | 73354 | 29462478 |
Arthralgia | 31.26 | 13.26 | 87 | 38608 | 139530 | 29396302 |
Generalised tonic-clonic seizure | 31.25 | 13.26 | 74 | 38621 | 19065 | 29516767 |
Panic attack | 31.17 | 13.26 | 46 | 38649 | 8280 | 29527552 |
Joint swelling | 31.06 | 13.26 | 13 | 38682 | 49617 | 29486215 |
Excessive eye blinking | 30.95 | 13.26 | 14 | 38681 | 436 | 29535396 |
Incorrect dose administered | 30.68 | 13.26 | 104 | 38591 | 32880 | 29502952 |
Cough | 30.63 | 13.26 | 76 | 38619 | 126651 | 29409181 |
Cataplexy | 30.57 | 13.26 | 12 | 38683 | 260 | 29535572 |
Nervousness | 29.45 | 13.26 | 53 | 38642 | 11253 | 29524579 |
Pain | 29.38 | 13.26 | 120 | 38575 | 171312 | 29364520 |
Pre-existing condition improved | 29.28 | 13.26 | 24 | 38671 | 2229 | 29533603 |
Phobia | 29.06 | 13.26 | 10 | 38685 | 147 | 29535685 |
Hyperhidrosis | 28.72 | 13.26 | 163 | 38532 | 64377 | 29471455 |
Peripheral coldness | 28.63 | 13.26 | 38 | 38657 | 6198 | 29529634 |
Infusion related reaction | 28.27 | 13.26 | 11 | 38684 | 43875 | 29491957 |
Sympathomimetic effect | 28.20 | 13.26 | 5 | 38690 | 0 | 29535832 |
Onychophagia | 27.97 | 13.26 | 8 | 38687 | 61 | 29535771 |
Gilbert's syndrome | 27.87 | 13.26 | 7 | 38688 | 30 | 29535802 |
Melaena | 27.52 | 13.26 | 4 | 38691 | 31172 | 29504660 |
Chronic kidney disease | 27.24 | 13.26 | 7 | 38688 | 36409 | 29499423 |
Malignant neoplasm progression | 27.17 | 13.26 | 34 | 38661 | 73825 | 29462007 |
Tourette's disorder | 27.00 | 13.26 | 8 | 38687 | 70 | 29535762 |
Metabolic acidosis | 26.76 | 13.26 | 8 | 38687 | 37654 | 29498178 |
Application site erosion | 26.70 | 13.26 | 8 | 38687 | 73 | 29535759 |
Drug withdrawal syndrome | 26.66 | 13.26 | 67 | 38628 | 17917 | 29517915 |
Pleural effusion | 26.56 | 13.26 | 33 | 38662 | 71875 | 29463957 |
Infection | 26.53 | 13.26 | 37 | 38658 | 76714 | 29459118 |
Hyponatraemia | 26.08 | 13.26 | 30 | 38665 | 67603 | 29468229 |
International normalised ratio increased | 25.63 | 13.26 | 13 | 38682 | 44359 | 29491473 |
Self-injurious ideation | 25.53 | 13.26 | 19 | 38676 | 1532 | 29534300 |
Device difficult to use | 25.15 | 13.26 | 19 | 38676 | 1567 | 29534265 |
Disease progression | 24.96 | 13.26 | 43 | 38652 | 81873 | 29453959 |
Change in sustained attention | 24.74 | 13.26 | 5 | 38690 | 5 | 29535827 |
Product dispensing error | 24.56 | 13.26 | 33 | 38662 | 5447 | 29530385 |
Mental disorder | 24.53 | 13.26 | 53 | 38642 | 12852 | 29522980 |
Dysphemia | 24.40 | 13.26 | 18 | 38677 | 1432 | 29534400 |
Rheumatoid arthritis | 24.40 | 13.26 | 6 | 38689 | 32146 | 29503686 |
Seizure | 24.12 | 13.26 | 206 | 38489 | 92917 | 29442915 |
Dermo-hypodermitis | 24.11 | 13.26 | 10 | 38685 | 251 | 29535581 |
Fall | 23.95 | 13.26 | 135 | 38560 | 177043 | 29358789 |
Cerebral congestion | 23.83 | 13.26 | 6 | 38689 | 26 | 29535806 |
Polydipsia psychogenic | 23.67 | 13.26 | 8 | 38687 | 111 | 29535721 |
Multiple cardiac defects | 23.55 | 13.26 | 7 | 38688 | 62 | 29535770 |
Substance use disorder | 23.50 | 13.26 | 10 | 38685 | 268 | 29535564 |
Oxygen saturation decreased | 23.33 | 13.26 | 15 | 38680 | 44922 | 29490910 |
Delayed puberty | 23.19 | 13.26 | 9 | 38686 | 189 | 29535643 |
Stereotypy | 23.14 | 13.26 | 13 | 38682 | 646 | 29535186 |
Pain in extremity | 23.11 | 13.26 | 71 | 38624 | 110362 | 29425470 |
Somnambulism | 22.94 | 13.26 | 23 | 38672 | 2775 | 29533057 |
Substance-induced psychotic disorder | 22.84 | 13.26 | 17 | 38678 | 1371 | 29534461 |
Neuropathy peripheral | 22.83 | 13.26 | 36 | 38659 | 70991 | 29464841 |
Erythema | 22.75 | 13.26 | 40 | 38655 | 75566 | 29460266 |
Distractibility | 22.71 | 13.26 | 10 | 38685 | 292 | 29535540 |
Adhesive tape use | 22.56 | 13.26 | 4 | 38691 | 0 | 29535832 |
Blood creatine phosphokinase increased | 22.45 | 13.26 | 109 | 38586 | 40535 | 29495297 |
Weight gain poor | 22.44 | 13.26 | 14 | 38681 | 845 | 29534987 |
Sudden death | 22.44 | 13.26 | 54 | 38641 | 14056 | 29521776 |
Illusion | 22.37 | 13.26 | 13 | 38682 | 689 | 29535143 |
Regressive behaviour | 22.21 | 13.26 | 6 | 38689 | 36 | 29535796 |
Acute psychosis | 21.99 | 13.26 | 18 | 38677 | 1669 | 29534163 |
Tongue spasm | 21.94 | 13.26 | 6 | 38689 | 38 | 29535794 |
Blood urea increased | 21.82 | 13.26 | 5 | 38690 | 28107 | 29507725 |
Petit mal epilepsy | 21.63 | 13.26 | 22 | 38673 | 2700 | 29533132 |
Colitis | 21.55 | 13.26 | 7 | 38688 | 31241 | 29504591 |
Constipation | 21.41 | 13.26 | 77 | 38618 | 114083 | 29421749 |
Dehydration | 21.13 | 13.26 | 78 | 38617 | 114670 | 29421162 |
Product residue present | 21.05 | 13.26 | 21 | 38674 | 2518 | 29533314 |
Oculogyric crisis | 20.91 | 13.26 | 16 | 38679 | 1345 | 29534487 |
Application site dryness | 20.72 | 13.26 | 6 | 38689 | 48 | 29535784 |
Erection increased | 20.66 | 13.26 | 11 | 38684 | 491 | 29535341 |
Negativism | 20.64 | 13.26 | 10 | 38685 | 365 | 29535467 |
Lactic acidosis | 20.46 | 13.26 | 7 | 38688 | 30240 | 29505592 |
Migraine | 20.23 | 13.26 | 48 | 38647 | 12382 | 29523450 |
Mucosal inflammation | 20.21 | 13.26 | 8 | 38687 | 31587 | 29504245 |
Muscle twitching | 20.11 | 13.26 | 37 | 38658 | 7989 | 29527843 |
Coronary artery disease | 20.03 | 13.26 | 17 | 38678 | 44173 | 29491659 |
Productive cough | 19.86 | 13.26 | 8 | 38687 | 31251 | 29504581 |
Plasma cell myeloma | 19.80 | 13.26 | 12 | 38683 | 37103 | 29498729 |
Renal disorder | 19.71 | 13.26 | 3 | 38692 | 22592 | 29513240 |
Liver disorder | 19.52 | 13.26 | 6 | 38689 | 27743 | 29508089 |
Suspiciousness | 19.39 | 13.26 | 9 | 38686 | 298 | 29535534 |
Ascites | 19.32 | 13.26 | 12 | 38683 | 36607 | 29499225 |
School refusal | 19.28 | 13.26 | 5 | 38690 | 25 | 29535807 |
Substance abuse | 19.21 | 13.26 | 33 | 38662 | 6754 | 29529078 |
Panic reaction | 19.20 | 13.26 | 15 | 38680 | 1300 | 29534532 |
Application site scab | 19.19 | 13.26 | 6 | 38689 | 64 | 29535768 |
Performance status decreased | 19.13 | 13.26 | 24 | 38671 | 3703 | 29532129 |
Scoliosis | 19.03 | 13.26 | 19 | 38676 | 2281 | 29533551 |
Incorrect route of product administration | 18.99 | 13.26 | 43 | 38652 | 10758 | 29525074 |
Poisoning | 18.94 | 13.26 | 41 | 38654 | 9952 | 29525880 |
C-reactive protein increased | 18.90 | 13.26 | 18 | 38677 | 44245 | 29491587 |
Accidental exposure to product by child | 18.82 | 13.26 | 15 | 38680 | 1339 | 29534493 |
Hypokalaemia | 18.57 | 13.26 | 23 | 38672 | 50180 | 29485652 |
Cholestasis | 18.56 | 13.26 | 4 | 38691 | 23458 | 29512374 |
Drug resistance | 18.47 | 13.26 | 3 | 38692 | 21537 | 29514295 |
Chorea | 18.39 | 13.26 | 13 | 38682 | 968 | 29534864 |
Shock | 18.31 | 13.26 | 3 | 38692 | 21401 | 29514431 |
Neutrophil count decreased | 18.27 | 13.26 | 18 | 38677 | 43549 | 29492283 |
Pneumonitis | 18.11 | 13.26 | 7 | 38688 | 28037 | 29507795 |
Abdominal distension | 18.10 | 13.26 | 20 | 38675 | 45891 | 29489941 |
Pericardial effusion | 18.08 | 13.26 | 3 | 38692 | 21205 | 29514627 |
Drooling | 18.03 | 13.26 | 21 | 38674 | 3000 | 29532832 |
Fear | 18.02 | 13.26 | 39 | 38656 | 9465 | 29526367 |
Hepatic function abnormal | 17.92 | 13.26 | 15 | 38680 | 39244 | 29496588 |
Off label use | 17.80 | 13.26 | 517 | 38178 | 300283 | 29235549 |
Hypocalcaemia | 17.45 | 13.26 | 3 | 38692 | 20662 | 29515170 |
Tri-iodothyronine increased | 17.38 | 13.26 | 5 | 38690 | 39 | 29535793 |
Insulin resistance | 17.31 | 13.26 | 10 | 38685 | 524 | 29535308 |
Physical assault | 17.22 | 13.26 | 13 | 38682 | 1071 | 29534761 |
Urinary incontinence | 17.15 | 13.26 | 54 | 38641 | 16427 | 29519405 |
Libido increased | 16.96 | 13.26 | 11 | 38684 | 710 | 29535122 |
Cardiac contusion | 16.92 | 13.26 | 3 | 38692 | 0 | 29535832 |
Limb girth decreased | 16.92 | 13.26 | 3 | 38692 | 0 | 29535832 |
Anorexia nervosa | 16.92 | 13.26 | 3 | 38692 | 0 | 29535832 |
Rash | 16.81 | 13.26 | 163 | 38532 | 189656 | 29346176 |
Testicular failure | 16.75 | 13.26 | 5 | 38690 | 45 | 29535787 |
Dyspnoea exertional | 16.58 | 13.26 | 14 | 38681 | 36476 | 29499356 |
Depersonalisation/derealisation disorder | 16.53 | 13.26 | 10 | 38685 | 571 | 29535261 |
Amnesia | 16.51 | 13.26 | 66 | 38629 | 22577 | 29513255 |
Weight increased | 16.50 | 13.26 | 163 | 38532 | 76504 | 29459328 |
Lower respiratory tract infection | 16.48 | 13.26 | 7 | 38688 | 26495 | 29509337 |
Poor quality product administered | 16.48 | 13.26 | 15 | 38680 | 1604 | 29534228 |
Drug reaction with eosinophilia and systemic symptoms | 16.47 | 13.26 | 8 | 38687 | 27984 | 29507848 |
Haematoma | 16.36 | 13.26 | 5 | 38690 | 23207 | 29512625 |
Sydenham's chorea | 16.35 | 13.26 | 4 | 38691 | 15 | 29535817 |
Idiopathic intracranial hypertension | 16.31 | 13.26 | 10 | 38685 | 585 | 29535247 |
Vision blurred | 16.27 | 13.26 | 99 | 38596 | 40077 | 29495755 |
Urinary tract infection | 16.23 | 13.26 | 45 | 38650 | 72309 | 29463523 |
Hypoxia | 16.21 | 13.26 | 23 | 38672 | 47356 | 29488476 |
Strabismus | 16.17 | 13.26 | 14 | 38681 | 1402 | 29534430 |
Pulmonary embolism | 16.15 | 13.26 | 49 | 38646 | 76485 | 29459347 |
Application site ulcer | 16.14 | 13.26 | 4 | 38691 | 16 | 29535816 |
Wolff-Parkinson-White syndrome | 16.10 | 13.26 | 7 | 38688 | 198 | 29535634 |
Opisthotonus | 16.06 | 13.26 | 9 | 38686 | 445 | 29535387 |
Acute respiratory distress syndrome | 16.06 | 13.26 | 5 | 38690 | 22930 | 29512902 |
Rectal haemorrhage | 16.02 | 13.26 | 13 | 38682 | 34536 | 29501296 |
Vasospasm | 15.93 | 13.26 | 8 | 38687 | 316 | 29535516 |
Bone marrow failure | 15.91 | 13.26 | 8 | 38687 | 27441 | 29508391 |
Therapeutic response changed | 15.90 | 13.26 | 8 | 38687 | 317 | 29535515 |
Stubbornness | 15.77 | 13.26 | 4 | 38691 | 18 | 29535814 |
Product dose omission issue | 15.73 | 13.26 | 194 | 38501 | 96189 | 29439643 |
Meningitis staphylococcal | 15.69 | 13.26 | 5 | 38690 | 57 | 29535775 |
Accommodation disorder | 15.57 | 13.26 | 7 | 38688 | 215 | 29535617 |
Daydreaming | 15.56 | 13.26 | 9 | 38686 | 473 | 29535359 |
Major depression | 15.54 | 13.26 | 22 | 38673 | 3813 | 29532019 |
Application site discolouration | 15.51 | 13.26 | 7 | 38688 | 217 | 29535615 |
Poor quality sleep | 15.25 | 13.26 | 31 | 38664 | 7202 | 29528630 |
Social anxiety disorder | 15.07 | 13.26 | 7 | 38688 | 232 | 29535600 |
Hypoglycaemia | 15.07 | 13.26 | 25 | 38670 | 48321 | 29487511 |
Parasomnia | 14.94 | 13.26 | 8 | 38687 | 361 | 29535471 |
Psychopathic personality | 14.85 | 13.26 | 3 | 38692 | 3 | 29535829 |
Stomatitis | 14.81 | 13.26 | 16 | 38679 | 37097 | 29498735 |
Injection site abscess | 14.71 | 13.26 | 10 | 38685 | 699 | 29535133 |
Eye movement disorder | 14.68 | 13.26 | 21 | 38674 | 3675 | 29532157 |
Thrombosis | 14.62 | 13.26 | 21 | 38674 | 43024 | 29492808 |
Lung disorder | 14.61 | 13.26 | 11 | 38684 | 30351 | 29505481 |
Inappropriate affect | 14.53 | 13.26 | 9 | 38686 | 536 | 29535296 |
Stress cardiomyopathy | 14.52 | 13.26 | 14 | 38681 | 1610 | 29534222 |
Initial insomnia | 14.45 | 13.26 | 18 | 38677 | 2757 | 29533075 |
Blood growth hormone decreased | 14.41 | 13.26 | 4 | 38691 | 27 | 29535805 |
Blood thyroid stimulating hormone increased | 14.38 | 13.26 | 19 | 38676 | 3086 | 29532746 |
Myocardial infarction | 14.36 | 13.26 | 85 | 38610 | 110211 | 29425621 |
Frustration tolerance decreased | 14.02 | 13.26 | 16 | 38679 | 2236 | 29533596 |
Epiphyses delayed fusion | 13.99 | 13.26 | 3 | 38692 | 5 | 29535827 |
Chronic obstructive pulmonary disease | 13.89 | 13.26 | 20 | 38675 | 40935 | 29494897 |
COVID-19 | 13.85 | 13.26 | 16 | 38679 | 35998 | 29499834 |
Electrocardiogram T wave inversion | 13.83 | 13.26 | 15 | 38680 | 1982 | 29533850 |
Back pain | 13.76 | 13.26 | 78 | 38617 | 102206 | 29433626 |
Sedation | 13.72 | 13.26 | 52 | 38643 | 17353 | 29518479 |
Personality change | 13.72 | 13.26 | 23 | 38672 | 4615 | 29531217 |
Schizotypal personality disorder | 13.63 | 13.26 | 3 | 38692 | 6 | 29535826 |
Sexual dysfunction | 13.57 | 13.26 | 26 | 38669 | 5788 | 29530044 |
Prescribed overdose | 13.56 | 13.26 | 33 | 38662 | 8650 | 29527182 |
Haemoptysis | 13.54 | 13.26 | 12 | 38683 | 30538 | 29505294 |
Therapeutic product effect increased | 13.47 | 13.26 | 9 | 38686 | 611 | 29535221 |
Dependence | 13.40 | 13.26 | 11 | 38684 | 1024 | 29534808 |
Nightmare | 13.37 | 13.26 | 39 | 38656 | 11378 | 29524454 |
Compulsions | 13.35 | 13.26 | 6 | 38689 | 184 | 29535648 |
Pressure of speech | 13.33 | 13.26 | 8 | 38687 | 450 | 29535382 |
Dysphoria | 13.26 | 13.26 | 15 | 38680 | 2077 | 29533755 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Aggression | 685.75 | 11.32 | 451 | 54997 | 45781 | 64397503 |
Agitation | 598.97 | 11.32 | 541 | 54907 | 87826 | 64355458 |
Product substitution issue | 511.43 | 11.32 | 267 | 55181 | 17594 | 64425690 |
Suicidal ideation | 501.92 | 11.32 | 433 | 55015 | 66109 | 64377175 |
Tic | 494.94 | 11.32 | 153 | 55295 | 2466 | 64440818 |
Abnormal behaviour | 452.75 | 11.32 | 309 | 55139 | 33313 | 64409971 |
Product quality issue | 427.85 | 11.32 | 285 | 55163 | 29514 | 64413770 |
Irritability | 416.58 | 11.32 | 304 | 55144 | 36442 | 64406842 |
No adverse event | 318.50 | 11.32 | 234 | 55214 | 28327 | 64414957 |
Attention deficit hyperactivity disorder | 298.83 | 11.32 | 106 | 55342 | 2664 | 64440620 |
Tachycardia | 289.92 | 11.32 | 486 | 54962 | 149093 | 64294191 |
Psychomotor hyperactivity | 284.79 | 11.32 | 169 | 55279 | 14282 | 64429002 |
Anxiety | 283.68 | 11.32 | 572 | 54876 | 202077 | 64241207 |
Dystonia | 269.69 | 11.32 | 180 | 55268 | 18685 | 64424599 |
Dyskinesia | 268.19 | 11.32 | 242 | 55206 | 39146 | 64404138 |
Disturbance in attention | 234.78 | 11.32 | 229 | 55219 | 40845 | 64402439 |
Psychotic disorder | 213.16 | 11.32 | 201 | 55247 | 34377 | 64408907 |
Suicide attempt | 211.04 | 11.32 | 282 | 55166 | 70725 | 64372559 |
Depression | 204.30 | 11.32 | 472 | 54976 | 182819 | 64260465 |
Toxicity to various agents | 194.95 | 11.32 | 720 | 54728 | 362793 | 64080491 |
Intentional overdose | 185.87 | 11.32 | 301 | 55147 | 89643 | 64353641 |
Insomnia | 185.85 | 11.32 | 477 | 54971 | 197359 | 64245925 |
Acute kidney injury | 173.36 | 11.32 | 85 | 55363 | 449155 | 63994129 |
Mydriasis | 171.89 | 11.32 | 126 | 55322 | 15186 | 64428098 |
Choreoathetosis | 166.12 | 11.32 | 58 | 55390 | 1389 | 64441895 |
Overdose | 163.74 | 11.32 | 398 | 55050 | 159168 | 64284116 |
Precocious puberty | 161.25 | 11.32 | 40 | 55408 | 266 | 64443018 |
Intentional product misuse | 160.45 | 11.32 | 250 | 55198 | 72045 | 64371239 |
Educational problem | 154.98 | 11.32 | 41 | 55407 | 363 | 64442921 |
Hallucination, visual | 154.95 | 11.32 | 153 | 55295 | 27681 | 64415603 |
Application site erythema | 151.27 | 11.32 | 76 | 55372 | 4613 | 64438671 |
Crying | 149.79 | 11.32 | 130 | 55318 | 19960 | 64423324 |
Growth retardation | 146.89 | 11.32 | 54 | 55394 | 1507 | 64441777 |
Hallucination | 144.14 | 11.32 | 239 | 55209 | 72549 | 64370735 |
Hallucination, auditory | 139.38 | 11.32 | 116 | 55332 | 16823 | 64426461 |
Product administration error | 128.64 | 11.32 | 138 | 55310 | 27505 | 64415779 |
Impulsive behaviour | 128.56 | 11.32 | 57 | 55391 | 2606 | 64440678 |
Anger | 127.86 | 11.32 | 107 | 55341 | 15634 | 64427650 |
Intentional self-injury | 123.01 | 11.32 | 138 | 55310 | 28906 | 64414378 |
Anaemia | 119.05 | 11.32 | 91 | 55357 | 378589 | 64064695 |
Wrong technique in product usage process | 118.91 | 11.32 | 206 | 55242 | 64768 | 64378516 |
Drug abuse | 118.86 | 11.32 | 314 | 55134 | 132060 | 64311224 |
Tremor | 117.59 | 11.32 | 336 | 55112 | 147894 | 64295390 |
Withdrawal syndrome | 115.92 | 11.32 | 121 | 55327 | 23371 | 64419913 |
Serotonin syndrome | 113.58 | 11.32 | 154 | 55294 | 39128 | 64404156 |
Diarrhoea | 112.88 | 11.32 | 288 | 55160 | 722416 | 63720868 |
Paranoia | 112.30 | 11.32 | 101 | 55347 | 16251 | 64427033 |
Trismus | 108.96 | 11.32 | 62 | 55386 | 4839 | 64438445 |
Drug dependence | 107.76 | 11.32 | 138 | 55310 | 33174 | 64410110 |
Priapism | 104.11 | 11.32 | 56 | 55392 | 3914 | 64439370 |
Product administered at inappropriate site | 102.06 | 11.32 | 51 | 55397 | 3059 | 64440225 |
Apathy | 100.98 | 11.32 | 81 | 55367 | 11151 | 64432133 |
Muscle contracture | 100.62 | 11.32 | 45 | 55403 | 2100 | 64441184 |
Hallucination, tactile | 98.83 | 11.32 | 30 | 55418 | 453 | 64442831 |
Bruxism | 97.51 | 11.32 | 52 | 55396 | 3572 | 64439712 |
Joint swelling | 97.20 | 11.32 | 32 | 55416 | 215350 | 64227934 |
Somnolence | 94.67 | 11.32 | 386 | 55062 | 203259 | 64240025 |
Oppositional defiant disorder | 94.39 | 11.32 | 29 | 55419 | 457 | 64442827 |
Pneumonia | 94.36 | 11.32 | 214 | 55234 | 559362 | 63883922 |
Mania | 93.38 | 11.32 | 91 | 55357 | 16195 | 64427089 |
Mood altered | 92.97 | 11.32 | 90 | 55358 | 15889 | 64427395 |
Application site irritation | 90.06 | 11.32 | 38 | 55410 | 1538 | 64441746 |
Completed suicide | 88.68 | 11.32 | 405 | 55043 | 224009 | 64219275 |
Incorrect product administration duration | 86.94 | 11.32 | 70 | 55378 | 9688 | 64433596 |
Death | 86.82 | 11.32 | 178 | 55270 | 482527 | 63960757 |
Cataplexy | 86.60 | 11.32 | 31 | 55417 | 800 | 64442484 |
Enuresis | 86.43 | 11.32 | 44 | 55404 | 2746 | 64440538 |
Euphoric mood | 84.93 | 11.32 | 59 | 55389 | 6532 | 64436752 |
Restlessness | 84.65 | 11.32 | 135 | 55313 | 39650 | 64403634 |
Homicidal ideation | 82.78 | 11.32 | 45 | 55403 | 3212 | 64440072 |
Obsessive-compulsive disorder | 81.21 | 11.32 | 51 | 55397 | 4767 | 64438517 |
Affect lability | 81.17 | 11.32 | 65 | 55383 | 8925 | 64434359 |
Febrile neutropenia | 79.35 | 11.32 | 31 | 55417 | 187626 | 64255658 |
Dyspnoea | 78.51 | 11.32 | 335 | 55113 | 718339 | 63724945 |
Chorea | 78.28 | 11.32 | 37 | 55411 | 1963 | 64441321 |
Peripheral swelling | 76.90 | 11.32 | 42 | 55406 | 209111 | 64234173 |
Coronary artery dissection | 76.56 | 11.32 | 29 | 55419 | 881 | 64442403 |
Emotional disorder | 75.21 | 11.32 | 72 | 55376 | 12535 | 64430749 |
Trichotillomania | 72.45 | 11.32 | 19 | 55429 | 162 | 64443122 |
Synovitis | 72.21 | 11.32 | 3 | 55445 | 99087 | 64344197 |
Logorrhoea | 71.02 | 11.32 | 44 | 55404 | 4015 | 64439269 |
Drug diversion | 70.32 | 11.32 | 29 | 55419 | 1107 | 64442177 |
Decreased eye contact | 70.27 | 11.32 | 26 | 55422 | 739 | 64442545 |
Depressed mood | 69.81 | 11.32 | 126 | 55322 | 40886 | 64402398 |
General physical health deterioration | 68.24 | 11.32 | 46 | 55402 | 204379 | 64238905 |
Arthralgia | 66.72 | 11.32 | 179 | 55269 | 442081 | 64001203 |
Rheumatoid arthritis | 66.44 | 11.32 | 29 | 55419 | 164265 | 64279019 |
Palpitations | 65.26 | 11.32 | 218 | 55230 | 104270 | 64339014 |
Neutropenia | 65.05 | 11.32 | 66 | 55382 | 239558 | 64203726 |
Sepsis | 64.19 | 11.32 | 62 | 55386 | 230279 | 64213005 |
Application site pruritus | 63.54 | 11.32 | 39 | 55409 | 3500 | 64439784 |
Feeling abnormal | 63.42 | 11.32 | 255 | 55193 | 133347 | 64309937 |
Heart rate increased | 62.63 | 11.32 | 207 | 55241 | 98468 | 64344816 |
Interstitial lung disease | 62.24 | 11.32 | 6 | 55442 | 97726 | 64345558 |
Headache | 60.98 | 11.32 | 709 | 54739 | 528758 | 63914526 |
Contraindicated product administered | 60.49 | 11.32 | 10 | 55438 | 107819 | 64335465 |
Delusion | 60.42 | 11.32 | 76 | 55372 | 17938 | 64425346 |
Muscle twitching | 60.33 | 11.32 | 78 | 55370 | 18920 | 64424364 |
Hypotension | 59.89 | 11.32 | 151 | 55297 | 380823 | 64062461 |
Thrombocytopenia | 59.21 | 11.32 | 63 | 55385 | 223738 | 64219546 |
Gastrointestinal haemorrhage | 59.06 | 11.32 | 20 | 55428 | 132292 | 64310992 |
Infusion related reaction | 59.04 | 11.32 | 34 | 55414 | 164433 | 64278851 |
Cardiac failure congestive | 57.83 | 11.32 | 20 | 55428 | 130560 | 64312724 |
Arthropathy | 56.27 | 11.32 | 17 | 55431 | 120950 | 64322334 |
Tardive dyskinesia | 55.86 | 11.32 | 53 | 55395 | 9125 | 64434159 |
Panic attack | 54.36 | 11.32 | 78 | 55370 | 20875 | 64422409 |
Extrapyramidal disorder | 54.01 | 11.32 | 75 | 55373 | 19477 | 64423807 |
Haemoglobin decreased | 53.76 | 11.32 | 53 | 55395 | 195010 | 64248274 |
Multiple organ dysfunction syndrome | 53.46 | 11.32 | 11 | 55437 | 101402 | 64341882 |
Gynaecomastia | 53.26 | 11.32 | 43 | 55405 | 5973 | 64437311 |
Lower respiratory tract infection | 52.57 | 11.32 | 9 | 55439 | 94605 | 64348679 |
Seizure | 52.21 | 11.32 | 282 | 55166 | 166610 | 64276674 |
Pulmonary malformation | 51.94 | 11.32 | 14 | 55434 | 134 | 64443150 |
Renal impairment | 51.25 | 11.32 | 26 | 55422 | 134991 | 64308293 |
Swelling | 50.89 | 11.32 | 38 | 55410 | 160180 | 64283104 |
Somnambulism | 50.35 | 11.32 | 39 | 55409 | 5102 | 64438182 |
Product taste abnormal | 49.04 | 11.32 | 27 | 55421 | 1976 | 64441308 |
Oromandibular dystonia | 48.81 | 11.32 | 21 | 55427 | 892 | 64442392 |
Rapid eye movement sleep behaviour disorder | 48.29 | 11.32 | 16 | 55432 | 325 | 64442959 |
Pancytopenia | 48.14 | 11.32 | 32 | 55416 | 143277 | 64300007 |
Sleep disorder | 47.91 | 11.32 | 136 | 55312 | 59573 | 64383711 |
Infection | 47.83 | 11.32 | 53 | 55395 | 184827 | 64258457 |
Social anxiety disorder | 47.70 | 11.32 | 17 | 55431 | 433 | 64442851 |
Drug intolerance | 46.36 | 11.32 | 56 | 55392 | 187936 | 64255348 |
Sleep apnoea syndrome | 46.18 | 11.32 | 88 | 55360 | 29744 | 64413540 |
Affective disorder | 45.88 | 11.32 | 41 | 55407 | 6539 | 64436745 |
Platelet count decreased | 45.71 | 11.32 | 46 | 55402 | 167665 | 64275619 |
Social avoidant behaviour | 45.57 | 11.32 | 35 | 55413 | 4522 | 64438762 |
Drug hypersensitivity | 44.97 | 11.32 | 85 | 55363 | 237730 | 64205554 |
Alice in wonderland syndrome | 44.95 | 11.32 | 10 | 55438 | 38 | 64443246 |
Renal failure | 44.93 | 11.32 | 54 | 55394 | 181634 | 64261650 |
Keratoconus | 44.76 | 11.32 | 11 | 55437 | 70 | 64443214 |
Treatment failure | 43.58 | 11.32 | 23 | 55425 | 116793 | 64326491 |
Decreased appetite | 43.36 | 11.32 | 400 | 55048 | 280889 | 64162395 |
Product administered to patient of inappropriate age | 43.11 | 11.32 | 34 | 55414 | 4567 | 64438717 |
Respiratory failure | 43.03 | 11.32 | 45 | 55403 | 161138 | 64282146 |
Pyrexia | 42.79 | 11.32 | 293 | 55155 | 558351 | 63884933 |
Hallucinations, mixed | 42.77 | 11.32 | 38 | 55410 | 6014 | 64437270 |
Increased appetite | 42.59 | 11.32 | 48 | 55400 | 10098 | 64433186 |
Ventricular parasystole | 42.42 | 11.32 | 7 | 55441 | 0 | 64443284 |
Hyperkalaemia | 42.24 | 11.32 | 17 | 55431 | 101112 | 64342172 |
Therapeutic response unexpected | 42.23 | 11.32 | 62 | 55386 | 16939 | 64426345 |
Drug withdrawal syndrome | 42.05 | 11.32 | 87 | 55361 | 31204 | 64412080 |
Systemic lupus erythematosus | 41.78 | 11.32 | 8 | 55440 | 77604 | 64365680 |
Application site rash | 41.51 | 11.32 | 24 | 55424 | 1930 | 64441354 |
Hyperhidrosis | 41.05 | 11.32 | 214 | 55234 | 124706 | 64318578 |
Mood swings | 40.95 | 11.32 | 62 | 55386 | 17406 | 64425878 |
Hyperkinesia | 40.54 | 11.32 | 26 | 55422 | 2520 | 64440764 |
Cardiac failure | 40.01 | 11.32 | 33 | 55415 | 132340 | 64310944 |
Disturbance in social behaviour | 39.19 | 11.32 | 30 | 55418 | 3857 | 64439427 |
Hypertension | 39.10 | 11.32 | 367 | 55081 | 258894 | 64184390 |
Atrial fibrillation | 39.05 | 11.32 | 54 | 55394 | 171035 | 64272249 |
Generalised tonic-clonic seizure | 38.24 | 11.32 | 97 | 55351 | 39760 | 64403524 |
Change in sustained attention | 38.09 | 11.32 | 7 | 55441 | 6 | 64443278 |
Speech disorder | 37.56 | 11.32 | 109 | 55339 | 48332 | 64394952 |
Suicidal behaviour | 37.56 | 11.32 | 26 | 55422 | 2861 | 64440423 |
Feeling jittery | 37.48 | 11.32 | 46 | 55402 | 10589 | 64432695 |
Lung cyst | 36.87 | 11.32 | 11 | 55437 | 156 | 64443128 |
Glossodynia | 36.28 | 11.32 | 6 | 55442 | 64690 | 64378594 |
Pain | 35.90 | 11.32 | 304 | 55144 | 553207 | 63890077 |
Nervousness | 34.92 | 11.32 | 78 | 55370 | 29478 | 64413806 |
Cough | 34.60 | 11.32 | 138 | 55310 | 302010 | 64141274 |
Petit mal epilepsy | 34.38 | 11.32 | 31 | 55417 | 5001 | 64438283 |
Torticollis | 34.09 | 11.32 | 22 | 55426 | 2155 | 64441129 |
Product adhesion issue | 34.02 | 11.32 | 23 | 55425 | 2436 | 64440848 |
Adhesive tape use | 33.93 | 11.32 | 6 | 55442 | 3 | 64443281 |
Excessive eye blinking | 33.67 | 11.32 | 18 | 55430 | 1242 | 64442042 |
Septic shock | 33.48 | 11.32 | 25 | 55423 | 105412 | 64337872 |
Mobility decreased | 33.37 | 11.32 | 16 | 55432 | 85824 | 64357460 |
Oculogyric crisis | 33.36 | 11.32 | 23 | 55425 | 2515 | 64440769 |
Incorrect dose administered | 32.92 | 11.32 | 121 | 55327 | 60644 | 64382640 |
Sudden death | 31.99 | 11.32 | 60 | 55388 | 20036 | 64423248 |
Treatment noncompliance | 31.96 | 11.32 | 96 | 55352 | 43386 | 64399898 |
Therapeutic response changed | 31.89 | 11.32 | 16 | 55432 | 968 | 64442316 |
Peripheral coldness | 31.54 | 11.32 | 48 | 55400 | 13536 | 64429748 |
Rash | 31.47 | 11.32 | 248 | 55200 | 458301 | 63984983 |
Raynaud's phenomenon | 31.40 | 11.32 | 16 | 55432 | 1000 | 64442284 |
Drug use disorder | 31.33 | 11.32 | 32 | 55416 | 6022 | 64437262 |
Stereotypy | 31.19 | 11.32 | 15 | 55433 | 827 | 64442457 |
School refusal | 30.98 | 11.32 | 7 | 55441 | 29 | 64443255 |
Pleural effusion | 30.87 | 11.32 | 38 | 55410 | 126521 | 64316763 |
Substance abuse | 30.84 | 11.32 | 39 | 55409 | 9253 | 64434031 |
Screaming | 30.77 | 11.32 | 25 | 55423 | 3504 | 64439780 |
Maternal exposure during breast feeding | 30.65 | 11.32 | 20 | 55428 | 1996 | 64441288 |
Solar urticaria | 30.53 | 11.32 | 8 | 55440 | 68 | 64443216 |
Oedema peripheral | 30.24 | 11.32 | 87 | 55361 | 210230 | 64233054 |
Negative thoughts | 30.18 | 11.32 | 17 | 55431 | 1301 | 64441983 |
Bipolar disorder | 30.13 | 11.32 | 33 | 55415 | 6728 | 64436556 |
Blister | 30.11 | 11.32 | 16 | 55432 | 80951 | 64362333 |
Formication | 30.08 | 11.32 | 27 | 55421 | 4330 | 64438954 |
Melaena | 29.95 | 11.32 | 5 | 55443 | 53543 | 64389741 |
Drug tolerance | 29.40 | 11.32 | 31 | 55417 | 6054 | 64437230 |
Delayed puberty | 29.11 | 11.32 | 9 | 55439 | 145 | 64443139 |
International normalised ratio increased | 28.92 | 11.32 | 16 | 55432 | 79151 | 64364133 |
Pericarditis | 28.68 | 11.32 | 9 | 55439 | 62507 | 64380777 |
Wound | 28.60 | 11.32 | 15 | 55433 | 76462 | 64366822 |
Parasomnia | 28.50 | 11.32 | 12 | 55436 | 483 | 64442801 |
Malignant neoplasm progression | 28.48 | 11.32 | 33 | 55415 | 112838 | 64330446 |
Substance use disorder | 28.38 | 11.32 | 11 | 55437 | 356 | 64442928 |
Hyperventilation | 28.10 | 11.32 | 32 | 55416 | 6808 | 64436476 |
Pre-existing condition improved | 28.03 | 11.32 | 27 | 55421 | 4735 | 64438549 |
Tachypnoea | 27.96 | 11.32 | 67 | 55381 | 26504 | 64416780 |
Blood creatine phosphokinase increased | 27.94 | 11.32 | 112 | 55336 | 58446 | 64384838 |
Blood creatinine increased | 27.94 | 11.32 | 46 | 55402 | 135736 | 64307548 |
Nightmare | 27.77 | 11.32 | 58 | 55390 | 20935 | 64422349 |
Protrusion tongue | 27.54 | 11.32 | 11 | 55437 | 386 | 64442898 |
Application site discolouration | 27.20 | 11.32 | 13 | 55435 | 707 | 64442577 |
Lactation disorder | 27.20 | 11.32 | 9 | 55439 | 182 | 64443102 |
Product prescribing error | 27.00 | 11.32 | 79 | 55369 | 35190 | 64408094 |
Body temperature increased | 26.99 | 11.32 | 81 | 55367 | 36585 | 64406699 |
Migraine | 26.87 | 11.32 | 116 | 55332 | 62561 | 64380723 |
Coordination abnormal | 26.77 | 11.32 | 47 | 55401 | 14917 | 64428367 |
Vasospasm | 26.77 | 11.32 | 14 | 55434 | 924 | 64442360 |
Drug reaction with eosinophilia and systemic symptoms | 26.35 | 11.32 | 7 | 55441 | 54210 | 64389074 |
Lactic acidosis | 26.17 | 11.32 | 10 | 55438 | 61400 | 64381884 |
Product complaint | 26.02 | 11.32 | 41 | 55407 | 11913 | 64431371 |
Erythema | 25.72 | 11.32 | 79 | 55369 | 186991 | 64256293 |
Hypersomnia | 25.53 | 11.32 | 54 | 55394 | 19663 | 64423621 |
Coronary artery disease | 25.49 | 11.32 | 10 | 55438 | 60423 | 64382861 |
Hyponatraemia | 25.49 | 11.32 | 56 | 55392 | 148283 | 64295001 |
Vision blurred | 25.16 | 11.32 | 148 | 55300 | 90168 | 64353116 |
Asthenia | 25.13 | 11.32 | 241 | 55207 | 427803 | 64015481 |
Application site urticaria | 25.11 | 11.32 | 9 | 55439 | 233 | 64443051 |
Erection increased | 25.01 | 11.32 | 10 | 55438 | 352 | 64442932 |
Strabismus | 24.92 | 11.32 | 18 | 55430 | 2119 | 64441165 |
Rectal haemorrhage | 24.83 | 11.32 | 11 | 55437 | 61806 | 64381478 |
White blood cell count decreased | 24.40 | 11.32 | 63 | 55385 | 157774 | 64285510 |
Optic disc haemorrhage | 24.39 | 11.32 | 7 | 55441 | 86 | 64443198 |
Urine amphetamine negative | 24.24 | 11.32 | 4 | 55444 | 0 | 64443284 |
Cardiac contusion | 24.24 | 11.32 | 4 | 55444 | 0 | 64443284 |
Testicular failure | 24.24 | 11.32 | 4 | 55444 | 0 | 64443284 |
Maternal exposure during pregnancy | 24.22 | 11.32 | 28 | 55420 | 95856 | 64347428 |
Hepatotoxicity | 24.05 | 11.32 | 3 | 55445 | 39959 | 64403325 |
Mental disorder | 23.96 | 11.32 | 63 | 55385 | 26382 | 64416902 |
Eye movement disorder | 23.95 | 11.32 | 30 | 55418 | 7049 | 64436235 |
Poisoning | 23.92 | 11.32 | 56 | 55392 | 21823 | 64421461 |
Autism spectrum disorder | 23.91 | 11.32 | 13 | 55435 | 928 | 64442356 |
Meningitis streptococcal | 23.90 | 11.32 | 8 | 55440 | 168 | 64443116 |
Mucosal inflammation | 23.81 | 11.32 | 12 | 55436 | 62572 | 64380712 |
Bone marrow failure | 23.67 | 11.32 | 6 | 55442 | 47946 | 64395338 |
Multiple sclerosis relapse | 23.20 | 11.32 | 83 | 55365 | 41052 | 64402232 |
Status epilepticus | 23.20 | 11.32 | 55 | 55393 | 21608 | 64421676 |
Exposure via breast milk | 23.09 | 11.32 | 12 | 55436 | 782 | 64442502 |
Abdominal discomfort | 22.99 | 11.32 | 80 | 55368 | 182242 | 64261042 |
Wound infection fungal | 22.97 | 11.32 | 8 | 55440 | 190 | 64443094 |
Memory impairment | 22.97 | 11.32 | 139 | 55309 | 85543 | 64357741 |
Dehydration | 22.94 | 11.32 | 102 | 55346 | 216661 | 64226623 |
Substance-induced psychotic disorder | 22.93 | 11.32 | 19 | 55429 | 2736 | 64440548 |
Product colour issue | 22.62 | 11.32 | 11 | 55437 | 622 | 64442662 |
Polydipsia psychogenic | 22.59 | 11.32 | 8 | 55440 | 200 | 64443084 |
Scoliosis | 22.56 | 11.32 | 27 | 55421 | 6055 | 64437229 |
Hepatic enzyme increased | 22.37 | 11.32 | 49 | 55399 | 129894 | 64313390 |
Poor quality product administered | 22.35 | 11.32 | 20 | 55428 | 3195 | 64440089 |
Tachyphrenia | 22.33 | 11.32 | 16 | 55432 | 1860 | 64441424 |
Hangover | 22.14 | 11.32 | 16 | 55432 | 1885 | 64441399 |
Pre-eclampsia | 22.03 | 11.32 | 27 | 55421 | 6204 | 64437080 |
Compulsions | 21.99 | 11.32 | 9 | 55439 | 337 | 64442947 |
Initial insomnia | 21.91 | 11.32 | 26 | 55422 | 5778 | 64437506 |
Product dispensing error | 21.84 | 11.32 | 37 | 55411 | 11413 | 64431871 |
Sympathomimetic effect | 21.59 | 11.32 | 6 | 55442 | 65 | 64443219 |
Disease progression | 21.56 | 11.32 | 57 | 55391 | 141623 | 64301661 |
Cyanosis | 21.33 | 11.32 | 54 | 55394 | 22101 | 64421183 |
Dermo-hypodermitis | 21.15 | 11.32 | 10 | 55438 | 531 | 64442753 |
Hunger | 21.02 | 11.32 | 22 | 55426 | 4259 | 64439025 |
Wolff-Parkinson-White syndrome | 20.73 | 11.32 | 8 | 55440 | 256 | 64443028 |
C-reactive protein increased | 20.61 | 11.32 | 31 | 55417 | 94878 | 64348406 |
Tongue spasm | 20.52 | 11.32 | 6 | 55442 | 79 | 64443205 |
Oxygen saturation decreased | 20.51 | 11.32 | 38 | 55410 | 107138 | 64336146 |
Weight gain poor | 20.50 | 11.32 | 11 | 55437 | 765 | 64442519 |
Self-injurious ideation | 20.49 | 11.32 | 19 | 55429 | 3178 | 64440106 |
Upper gastrointestinal haemorrhage | 20.35 | 11.32 | 3 | 55445 | 35217 | 64408067 |
Panic reaction | 20.32 | 11.32 | 21 | 55427 | 4006 | 64439278 |
Psychiatric symptom | 20.30 | 11.32 | 26 | 55422 | 6247 | 64437037 |
Abdominal distension | 20.23 | 11.32 | 32 | 55416 | 95962 | 64347322 |
Drug screen negative | 20.22 | 11.32 | 8 | 55440 | 274 | 64443010 |
Splenic infarction | 20.18 | 11.32 | 19 | 55429 | 3238 | 64440046 |
Onychophagia | 20.05 | 11.32 | 6 | 55442 | 86 | 64443198 |
Incorrect route of product administration | 19.60 | 11.32 | 54 | 55394 | 23244 | 64420040 |
Burnout syndrome | 19.53 | 11.32 | 8 | 55440 | 300 | 64442984 |
Narcolepsy | 19.53 | 11.32 | 12 | 55436 | 1079 | 64442205 |
Distractibility | 19.46 | 11.32 | 10 | 55438 | 636 | 64442648 |
Hepatic function abnormal | 19.46 | 11.32 | 16 | 55432 | 64297 | 64378987 |
Respiratory tract malformation | 19.46 | 11.32 | 5 | 55443 | 39 | 64443245 |
Osteoporosis | 19.40 | 11.32 | 6 | 55442 | 42074 | 64401210 |
Chronic kidney disease | 19.35 | 11.32 | 13 | 55435 | 57906 | 64385378 |
Grimacing | 19.19 | 11.32 | 10 | 55438 | 655 | 64442629 |
Hypocalcaemia | 19.17 | 11.32 | 6 | 55442 | 41747 | 64401537 |
Stomatitis | 19.13 | 11.32 | 41 | 55407 | 109564 | 64333720 |
Akathisia | 19.12 | 11.32 | 35 | 55413 | 11475 | 64431809 |
Cataract subcapsular | 19.10 | 11.32 | 11 | 55437 | 878 | 64442406 |
Sinus tachycardia | 19.06 | 11.32 | 66 | 55382 | 32122 | 64411162 |
Thinking abnormal | 19.02 | 11.32 | 35 | 55413 | 11521 | 64431763 |
Dermatillomania | 18.98 | 11.32 | 7 | 55441 | 197 | 64443087 |
Sleep-related eating disorder | 18.95 | 11.32 | 10 | 55438 | 672 | 64442612 |
Hypoglycaemia | 18.91 | 11.32 | 30 | 55418 | 89862 | 64353422 |
Cerebral congestion | 18.83 | 11.32 | 5 | 55443 | 45 | 64443239 |
Agranulocytosis | 18.46 | 11.32 | 5 | 55443 | 38224 | 64405060 |
Long QT syndrome congenital | 18.44 | 11.32 | 5 | 55443 | 49 | 64443235 |
Atrioventricular block second degree | 18.19 | 11.32 | 25 | 55423 | 6429 | 64436855 |
Limb girth decreased | 18.18 | 11.32 | 3 | 55445 | 0 | 64443284 |
Herpes zoster | 18.05 | 11.32 | 25 | 55423 | 79162 | 64364122 |
Poor quality sleep | 18.05 | 11.32 | 46 | 55402 | 18905 | 64424379 |
Open angle glaucoma | 17.93 | 11.32 | 8 | 55440 | 371 | 64442913 |
Phobia | 17.83 | 11.32 | 8 | 55440 | 376 | 64442908 |
Illusion | 17.80 | 11.32 | 13 | 55435 | 1557 | 64441727 |
Disinhibition | 17.70 | 11.32 | 15 | 55433 | 2228 | 64441056 |
Inflammation | 17.68 | 11.32 | 18 | 55430 | 65282 | 64378002 |
Sensory level abnormal | 17.62 | 11.32 | 6 | 55442 | 133 | 64443151 |
Loss of consciousness | 17.56 | 11.32 | 200 | 55248 | 148165 | 64295119 |
Fear | 17.21 | 11.32 | 47 | 55401 | 20124 | 64423160 |
Dysphoria | 17.14 | 11.32 | 20 | 55428 | 4368 | 64438916 |
Hypnagogic hallucination | 17.13 | 11.32 | 6 | 55442 | 145 | 64443139 |
Amnesia | 16.75 | 11.32 | 84 | 55364 | 48185 | 64395099 |
Anaphylactic shock | 16.59 | 11.32 | 3 | 55445 | 30325 | 64412959 |
Product residue present | 16.53 | 11.32 | 17 | 55431 | 3225 | 64440059 |
Hepatic failure | 16.49 | 11.32 | 14 | 55434 | 55380 | 64387904 |
Oedema | 16.37 | 11.32 | 34 | 55414 | 91901 | 64351383 |
Accidental exposure to product by child | 16.37 | 11.32 | 15 | 55433 | 2470 | 64440814 |
Opisthotonus | 16.30 | 11.32 | 9 | 55439 | 662 | 64442622 |
Hypoxia | 16.21 | 11.32 | 32 | 55416 | 88117 | 64355167 |
Tourette's disorder | 16.14 | 11.32 | 5 | 55443 | 81 | 64443203 |
Chronic fatigue syndrome | 16.11 | 11.32 | 11 | 55437 | 1184 | 64442100 |
Bisexuality | 16.10 | 11.32 | 3 | 55445 | 3 | 64443281 |
Neutrophil count decreased | 16.02 | 11.32 | 26 | 55422 | 77170 | 64366114 |
Prescribed overdose | 16.00 | 11.32 | 46 | 55402 | 20285 | 64422999 |
Psoriasis | 15.98 | 11.32 | 23 | 55425 | 71680 | 64371604 |
Regressive behaviour | 15.98 | 11.32 | 5 | 55443 | 84 | 64443200 |
Toxic epidermal necrolysis | 15.92 | 11.32 | 6 | 55442 | 37160 | 64406124 |
Major depression | 15.90 | 11.32 | 26 | 55422 | 7790 | 64435494 |
Pruritus | 15.82 | 11.32 | 182 | 55266 | 312218 | 64131066 |
Hyperphagia | 15.75 | 11.32 | 14 | 55434 | 2217 | 64441067 |
Pericardial effusion | 15.74 | 11.32 | 7 | 55441 | 39247 | 64404037 |
Tooth discolouration | 15.72 | 11.32 | 10 | 55438 | 955 | 64442329 |
Concussion | 15.61 | 11.32 | 26 | 55422 | 7912 | 64435372 |
Nystagmus | 15.60 | 11.32 | 28 | 55420 | 9040 | 64434244 |
Bundle branch block right | 15.53 | 11.32 | 30 | 55418 | 10239 | 64433045 |
Brain oedema | 15.53 | 11.32 | 48 | 55400 | 22027 | 64421257 |
Antiphospholipid syndrome | 15.49 | 11.32 | 12 | 55436 | 1570 | 64441714 |
Osteoarthritis | 15.46 | 11.32 | 19 | 55429 | 63317 | 64379967 |
Injection site pain | 15.34 | 11.32 | 47 | 55401 | 111361 | 64331923 |
Hyperacusis | 15.34 | 11.32 | 13 | 55435 | 1932 | 64441352 |
Negativism | 15.26 | 11.32 | 9 | 55439 | 751 | 64442533 |
Meningitis staphylococcal | 15.21 | 11.32 | 5 | 55443 | 99 | 64443185 |
Hypokalaemia | 15.02 | 11.32 | 54 | 55394 | 121849 | 64321435 |
Sleep paralysis | 14.99 | 11.32 | 8 | 55440 | 550 | 64442734 |
Eosinophilia | 14.94 | 11.32 | 7 | 55441 | 38069 | 64405215 |
Substance abuser | 14.89 | 11.32 | 5 | 55443 | 106 | 64443178 |
Staring | 14.82 | 11.32 | 14 | 55434 | 2396 | 64440888 |
Application site erosion | 14.80 | 11.32 | 6 | 55442 | 219 | 64443065 |
Wrong product administered | 14.80 | 11.32 | 25 | 55423 | 7695 | 64435589 |
Ascites | 14.71 | 11.32 | 19 | 55429 | 61982 | 64381302 |
Product use issue | 14.71 | 11.32 | 197 | 55251 | 151518 | 64291766 |
Livedo reticularis | 14.69 | 11.32 | 17 | 55431 | 3680 | 64439604 |
Injection site abscess | 14.56 | 11.32 | 11 | 55437 | 1387 | 64441897 |
Insulin resistance | 14.53 | 11.32 | 10 | 55438 | 1090 | 64442194 |
Plasma cell myeloma | 14.52 | 11.32 | 11 | 55437 | 46064 | 64397220 |
Myelodysplastic syndrome | 14.51 | 11.32 | 3 | 55445 | 27576 | 64415708 |
Acute psychosis | 14.48 | 11.32 | 17 | 55431 | 3735 | 64439549 |
Leukopenia | 14.45 | 11.32 | 42 | 55406 | 101200 | 64342084 |
Sudden onset of sleep | 14.41 | 11.32 | 8 | 55440 | 595 | 64442689 |
Talipes | 14.39 | 11.32 | 5 | 55443 | 118 | 64443166 |
Application site pain | 14.37 | 11.32 | 18 | 55430 | 4230 | 64439054 |
Eosinophilic myocarditis | 14.31 | 11.32 | 9 | 55439 | 843 | 64442441 |
Surgery | 14.29 | 11.32 | 55 | 55393 | 28158 | 64415126 |
Epiphyses delayed fusion | 14.29 | 11.32 | 3 | 55445 | 8 | 64443276 |
Hypertonia | 14.19 | 11.32 | 22 | 55426 | 6303 | 64436981 |
Congestive cardiomyopathy | 14.18 | 11.32 | 29 | 55419 | 10315 | 64432969 |
Hyperglycaemia | 14.14 | 11.32 | 19 | 55429 | 60949 | 64382335 |
Schizotypal personality disorder | 14.03 | 11.32 | 3 | 55445 | 9 | 64443275 |
Hepatocellular injury | 14.00 | 11.32 | 11 | 55437 | 45224 | 64398060 |
Electrocardiogram QRS complex prolonged | 13.97 | 11.32 | 27 | 55421 | 9217 | 64434067 |
Schizoaffective disorder bipolar type | 13.93 | 11.32 | 5 | 55443 | 130 | 64443154 |
Constipation | 13.91 | 11.32 | 128 | 55320 | 229209 | 64214075 |
Drug ineffective | 13.80 | 11.32 | 867 | 54581 | 839380 | 63603904 |
Drug eruption | 13.64 | 11.32 | 7 | 55441 | 36129 | 64407155 |
Injection site erythema | 13.63 | 11.32 | 25 | 55423 | 70775 | 64372509 |
Physical assault | 13.58 | 11.32 | 11 | 55437 | 1535 | 64441749 |
Shock | 13.57 | 11.32 | 8 | 55440 | 38232 | 64405052 |
Dysphemia | 13.51 | 11.32 | 15 | 55433 | 3104 | 64440180 |
Palmar-plantar erythrodysaesthesia syndrome | 13.49 | 11.32 | 4 | 55444 | 28815 | 64414469 |
Dyspnoea exertional | 13.36 | 11.32 | 27 | 55421 | 73703 | 64369581 |
Urinary incontinence | 13.32 | 11.32 | 64 | 55384 | 36087 | 64407197 |
Arthritis | 13.30 | 11.32 | 33 | 55415 | 83781 | 64359503 |
Haematochezia | 13.17 | 11.32 | 23 | 55425 | 66350 | 64376934 |
Poor sucking reflex | 13.14 | 11.32 | 4 | 55444 | 61 | 64443223 |
Chills | 13.10 | 11.32 | 67 | 55381 | 137197 | 64306087 |
Liver disorder | 13.02 | 11.32 | 16 | 55432 | 53335 | 64389949 |
Hypomagnesaemia | 13.01 | 11.32 | 8 | 55440 | 37368 | 64405916 |
Hepatitis | 12.99 | 11.32 | 12 | 55436 | 45570 | 64397714 |
Pressure of speech | 12.99 | 11.32 | 9 | 55439 | 992 | 64442292 |
Electroencephalogram abnormal | 12.96 | 11.32 | 19 | 55429 | 5184 | 64438100 |
Sedation | 12.90 | 11.32 | 70 | 55378 | 41392 | 64401892 |
Impaired healing | 12.89 | 11.32 | 20 | 55428 | 60453 | 64382831 |
Myocarditis | 12.87 | 11.32 | 38 | 55410 | 17005 | 64426279 |
Personality change | 12.87 | 11.32 | 25 | 55423 | 8568 | 64434716 |
Water intoxication | 12.79 | 11.32 | 8 | 55440 | 742 | 64442542 |
Drug abuser | 12.75 | 11.32 | 20 | 55428 | 5788 | 64437496 |
Libido decreased | 12.69 | 11.32 | 18 | 55430 | 4766 | 64438518 |
Neoplasm progression | 12.63 | 11.32 | 10 | 55438 | 40954 | 64402330 |
Gastric bypass | 12.60 | 11.32 | 9 | 55439 | 1041 | 64442243 |
COVID-19 | 12.54 | 11.32 | 23 | 55425 | 65117 | 64378167 |
Hepatitis C virus test positive | 12.51 | 11.32 | 6 | 55442 | 329 | 64442955 |
Product dose omission issue | 12.49 | 11.32 | 236 | 55212 | 194511 | 64248773 |
Full blood count abnormal | 12.42 | 11.32 | 5 | 55443 | 29752 | 64413532 |
Pneumonitis | 12.40 | 11.32 | 15 | 55433 | 50350 | 64392934 |
Learning disorder | 12.39 | 11.32 | 7 | 55441 | 539 | 64442745 |
Psychotic symptom | 12.35 | 11.32 | 12 | 55436 | 2126 | 64441158 |
Gastrointestinal disorder | 12.24 | 11.32 | 38 | 55410 | 89671 | 64353613 |
Haematoma | 12.23 | 11.32 | 13 | 55435 | 46237 | 64397047 |
Gastrooesophageal reflux disease | 12.23 | 11.32 | 34 | 55414 | 83109 | 64360175 |
Sydenham's chorea | 12.22 | 11.32 | 3 | 55445 | 19 | 64443265 |
Asphyxia | 12.16 | 11.32 | 26 | 55422 | 9540 | 64433744 |
Defect conduction intraventricular | 12.10 | 11.32 | 6 | 55442 | 354 | 64442930 |
Autophobia | 12.09 | 11.32 | 3 | 55445 | 20 | 64443264 |
Bezoar | 12.05 | 11.32 | 12 | 55436 | 2191 | 64441093 |
Henoch-Schonlein purpura | 12.04 | 11.32 | 12 | 55436 | 2194 | 64441090 |
Electrocardiogram ST segment elevation | 11.96 | 11.32 | 22 | 55426 | 7237 | 64436047 |
Osteonecrosis of jaw | 11.94 | 11.32 | 10 | 55438 | 39815 | 64403469 |
Thrombosis | 11.85 | 11.32 | 27 | 55421 | 70615 | 64372669 |
Application site scab | 11.81 | 11.32 | 5 | 55443 | 204 | 64443080 |
Arrhythmia | 11.80 | 11.32 | 82 | 55366 | 52862 | 64390422 |
Hypomania | 11.77 | 11.32 | 19 | 55429 | 5635 | 64437649 |
Hypersensitivity | 11.76 | 11.32 | 110 | 55338 | 196342 | 64246942 |
Renal disorder | 11.73 | 11.32 | 8 | 55440 | 35357 | 64407927 |
Muscle tightness | 11.66 | 11.32 | 28 | 55420 | 11087 | 64432197 |
Myocardial infarction | 11.65 | 11.32 | 89 | 55359 | 165732 | 64277552 |
Injection site swelling | 11.65 | 11.32 | 11 | 55437 | 41342 | 64401942 |
Rash maculo-papular | 11.59 | 11.32 | 14 | 55434 | 47012 | 64396272 |
Persecutory delusion | 11.56 | 11.32 | 16 | 55432 | 4142 | 64439142 |
Verbigeration | 11.50 | 11.32 | 3 | 55445 | 25 | 64443259 |
Streptococcal infection | 11.50 | 11.32 | 22 | 55426 | 7457 | 64435827 |
None
Source | Code | Description |
---|---|---|
ATC | N06BA04 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D000697 | Central Nervous System Stimulants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018765 | Dopamine Uptake Inhibitors |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
CHEBI has role | CHEBI:35337 | analeptic |
CHEBI has role | CHEBI:35471 | psychotropic drugs |
CHEBI has role | CHEBI:35524 | sympathomimetic |
CHEBI has role | CHEBI:35640 | adrenergic uptake inhibitors |
CHEBI has role | CHEBI:37962 | adrenergic agents |
CHEBI has role | CHEBI:51039 | dopamine reuptake inhibitor |
FDA PE | N0000175729 | Central Nervous System Stimulation |
FDA EPC | N0000175739 | Central Nervous System Stimulant |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Narcolepsy | indication | 60380001 | DOID:8986 |
Attention deficit hyperactivity disorder | indication | 406506008 | |
Depressive disorder | off-label use | 35489007 | |
Cognitive Impairment following Traumatic Brain Injury | off-label use | ||
Gilles de la Tourette's syndrome | contraindication | 5158005 | DOID:11119 |
Dependent drug abuse | contraindication | 6525002 | |
Alcoholism | contraindication | 7200002 | |
Sinus tachycardia | contraindication | 11092001 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Mood swings | contraindication | 18963009 | |
Lowered convulsive threshold | contraindication | 19260006 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Feeling agitated | contraindication | 24199005 | |
Short bowel syndrome | contraindication | 26629001 | DOID:10605 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Tension | contraindication | 53489000 | |
Anorexia nervosa | contraindication | 56882008 | DOID:8689 |
Aggressive behavior | contraindication | 61372001 | |
Substance abuse | contraindication | 66214007 | |
Psychotic disorder | contraindication | 69322001 | |
Severe anxiety (panic) | contraindication | 80583007 | |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Cardiomyopathy | contraindication | 85898001 | DOID:0050700 |
Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
Blurring of visual image | contraindication | 111516008 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Structural disorder of heart | contraindication | 128599005 | |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Motor tic disorder | contraindication | 230337001 | |
Cerebrovascular accident | contraindication | 230690007 | |
Mania | contraindication | 231494001 | |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Anemia | contraindication | 271737000 | DOID:2355 |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Visual impairment | contraindication | 397540003 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Hypertensive urgency | contraindication | 443482000 | |
Life-Threatening Cardiac Arrhythmias | contraindication | ||
Uncontrolled Epilepsy | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.68 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10MG/9HR (1.1MG/HR) | DAYTRANA | NOVEN PHARMS INC | N021514 | April 6, 2006 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9668981 | Oct. 7, 2025 | METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF |
15MG/9HR (1.6MG/HR) | DAYTRANA | NOVEN PHARMS INC | N021514 | April 6, 2006 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9668981 | Oct. 7, 2025 | METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF |
20MG/9HR (2.2MG/HR) | DAYTRANA | NOVEN PHARMS INC | N021514 | April 6, 2006 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9668981 | Oct. 7, 2025 | METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF |
30MG/9HR (3.3MG/HR) | DAYTRANA | NOVEN PHARMS INC | N021514 | April 6, 2006 | RX | FILM, EXTENDED RELEASE | TRANSDERMAL | 9668981 | Oct. 7, 2025 | METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF |
5MG/ML | QUILLIVANT XR | NEXTWAVE | N202100 | Sept. 27, 2012 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 8465765 | Feb. 15, 2031 | TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2 |
5MG/ML | QUILLIVANT XR | NEXTWAVE | N202100 | Sept. 27, 2012 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 8563033 | Feb. 15, 2031 | TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2 |
5MG/ML | QUILLIVANT XR | NEXTWAVE | N202100 | Sept. 27, 2012 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 8778390 | Feb. 15, 2031 | TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23 |
5MG/ML | QUILLIVANT XR | NEXTWAVE | N202100 | Sept. 27, 2012 | RX | FOR SUSPENSION, EXTENDED RELEASE | ORAL | 8956649 | Feb. 15, 2031 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1 |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292937 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10617651 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10881618 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11241391 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8916588 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9028868 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9034902 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
100MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9603809 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292937 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10617651 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10881618 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11241391 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8916588 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9028868 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9034902 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9603809 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292937 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10617651 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10881618 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11241391 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8916588 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9028868 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9034902 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
40MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9603809 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292937 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10617651 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10881618 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11241391 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8916588 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9028868 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9034902 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
60MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9603809 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292937 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10617651 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10881618 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 11241391 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 8916588 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9028868 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9034902 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
80MG | JORNAY PM | IRONSHORE PHARMS | N209311 | Aug. 8, 2018 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 9603809 | March 23, 2032 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
20MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 10857143 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
20MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 11103495 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
20MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9295642 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
20MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9545399 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
20MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9844544 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED |
30MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 10857143 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
30MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 11103495 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
30MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9295642 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
30MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9545399 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
30MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9844544 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED |
40MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 10857143 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
40MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 11103495 | Aug. 14, 2033 | A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED |
40MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9295642 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
40MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9545399 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
40MG | QUILLICHEW ER | NEXTWAVE PHARMS | N207960 | Dec. 4, 2015 | RX | TABLET, EXTENDED RELEASE, CHEWABLE | ORAL | 9844544 | Aug. 14, 2033 | A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10111839 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10292939 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10449159 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10500162 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10512613 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10568841 | Oct. 30, 2035 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
17.3MG | COTEMPLA XR-ODT | NEOS THERAPS INC | N205489 | June 19, 2017 | RX | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE | ORAL | 11166947 | Jan. 25, 2038 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS |
25.9MG | COTEMPLA XR-ODT | NEOS THERAPS INC | N205489 | June 19, 2017 | RX | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE | ORAL | 11166947 | Jan. 25, 2038 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS |
8.6MG | COTEMPLA XR-ODT | NEOS THERAPS INC | N205489 | June 19, 2017 | RX | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE | ORAL | 11166947 | Jan. 25, 2038 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | 10722473 | Nov. 19, 2038 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | Feb. 27, 2022 | NEW PRODUCT |
25MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
35MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
45MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
55MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
70MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
85MG | ADHANSIA XR | PURDUE PHARMA LP | N212038 | Feb. 27, 2019 | RX | CAPSULE, EXTENDED RELEASE | ORAL | June 28, 2024 | LABELING REVISIONS RELATED TO CLINICAL STUDIES |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent dopamine transporter | Transporter | INHIBITOR | Ki | 6.96 | CHEMBL | CHEMBL | |||
Sodium-dependent noradrenaline transporter | Transporter | INHIBITOR | Ki | 6.18 | CHEMBL | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.25 | PDSP | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.07 | PDSP | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.62 | PDSP | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 4.19 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | IC50 | 7.08 | CHEMBL |
ID | Source |
---|---|
4019832 | VUID |
N0000147920 | NUI |
D01296 | KEGG_DRUG |
23655-65-4 | SECONDARY_CAS_RN |
4018198 | VANDF |
4019832 | VANDF |
C0025810 | UMLSCUI |
CHEBI:6887 | CHEBI |
CHEMBL796 | ChEMBL_ID |
DB00422 | DRUGBANK_ID |
CHEMBL1722 | ChEMBL_ID |
D008774 | MESH_DESCRIPTOR_UI |
4158 | PUBCHEM_CID |
485 | INN_ID |
7236 | IUPHAR_LIGAND_ID |
207ZZ9QZ49 | UNII |
203188 | RXNORM |
1038 | MMSL |
32827 | MMSL |
37867 | MMSL |
5092 | MMSL |
d00900 | MMSL |
001540 | NDDF |
004619 | NDDF |
18548003 | SNOMEDCT_US |
373337007 | SNOMEDCT_US |
42163009 | SNOMEDCT_US |
20748-11-2 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ritalin LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0370 | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | NDA | 33 sections |
Ritalin LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0371 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | NDA | 33 sections |
Ritalin LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0372 | CAPSULE, EXTENDED RELEASE | 40 mg | ORAL | NDA | 33 sections |
Ritalin LA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0424 | CAPSULE, EXTENDED RELEASE | 10 mg | ORAL | NDA | 33 sections |
Ritalin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0439 | TABLET | 5 mg | ORAL | NDA | 30 sections |
Ritalin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0440 | TABLET | 10 mg | ORAL | NDA | 30 sections |
Ritalin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0441 | TABLET | 20 mg | ORAL | NDA | 30 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5292 | CAPSULE, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5292 | CAPSULE, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5293 | CAPSULE, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5293 | CAPSULE, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5295 | CAPSULE, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5295 | CAPSULE, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5296 | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5296 | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5297 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5297 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5298 | CAPSULE, EXTENDED RELEASE | 40 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(CD) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5298 | CAPSULE, EXTENDED RELEASE | 40 mg | ORAL | ANDA | 34 sections |
Methylphenidate Hydrochloride(LA) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5346 | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | ANDA | 29 sections |
Methylphenidate Hydrochloride(LA) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5347 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 29 sections |
Methylphenidate Hydrochloride(LA) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5348 | CAPSULE, EXTENDED RELEASE | 40 mg | ORAL | ANDA | 29 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1736 | CAPSULE, EXTENDED RELEASE | 10 mg | ORAL | ANDA | 15 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1737 | CAPSULE, EXTENDED RELEASE | 20 mg | ORAL | ANDA | 15 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1738 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | ANDA | 15 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1739 | CAPSULE, EXTENDED RELEASE | 40 mg | ORAL | ANDA | 15 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1740 | CAPSULE, EXTENDED RELEASE | 50 mg | ORAL | ANDA | 15 sections |
Methylphenidate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1741 | CAPSULE, EXTENDED RELEASE | 60 mg | ORAL | ANDA | 15 sections |
METHYLPHENIDATE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1800 | TABLET | 5 mg | ORAL | ANDA | 27 sections |
METHYLPHENIDATE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1801 | TABLET | 10 mg | ORAL | ANDA | 27 sections |